Page last updated: 2024-11-04

trazodone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5533
CHEMBL ID621
CHEBI ID9654
SCHEMBL ID28167
MeSH IDM0021855

Synonyms (119)

Synonym
AC-6778
bdbm50073444
AB00053648-14
BRD-K70778732-003-05-1
gtpl213
DIVK1C_000196
KBIO1_000196
8-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride
SPECTRUM_001424
PRESTWICK2_000292
NCGC00016035-01
lopac-t-6154
BPBIO1_000248
OPREA1_185901
SPECTRUM5_000974
PRESTWICK3_000292
IDI1_000196
BSPBIO_000224
CHEBI:9654 ,
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one
trazodona
trazodonum
C07156
19794-93-5
trazodone
2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one
DB00656
beneficat
trazodona [inn-spanish]
trazodone [inn:ban]
trazonil
trazodonum [inn-latin]
1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-
sideril
trazodona [spanish]
desirel
trazalon
s-triazolo(4,3-a)pyridin-3(2h)-one, 2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-
brn 0628010
trazodonum [latin]
einecs 243-317-1
trazodon
hsdb 7048
trittico
tradozone
trazodil
KBIO2_007040
KBIO3_002540
KBIOGR_001110
KBIO2_001904
KBIOSS_001904
KBIO2_004472
SPECTRUM4_000755
SPECTRUM3_001560
PRESTWICK1_000292
NINDS_000196
SPBIO_002443
SPECTRUM2_000854
SPBIO_000867
PRESTWICK0_000292
LOPAC0_001159
BSPBIO_003040
NCGC00016035-03
NCGC00024405-03
NCGC00016035-09
j10.767k ,
CHEMBL621 ,
L000771
trazodone (inn)
trittico (tn)
D08626
FT-0658382
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one
ec 243-317-1
unii-ybk48bxk30
ybk48bxk30 ,
CCG-205233
NCGC00016035-06
NCGC00016035-05
NCGC00016035-08
NCGC00016035-04
NCGC00016035-07
NCGC00016035-10
NCGC00016035-12
trazodone [who-dd]
trazodone [vandf]
trazodone [inn]
trazodone [mi]
2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-s-triazolo(4,3-a)pyridin-3(2h)-one
AKOS015896423
S5857
2-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one
SCHEMBL28167
DTXSID5045043 ,
1,2,4-triazolo[4,3-a]pyridin-3(2h)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-
2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one #
AB00053648_15
AB00053648_16
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2h,3h-[1,2,4]triazolo[4,3-a]pyridin-3-one
SBI-0051126.P003
BCP07176
Q411457
19794-93-5 (free)
1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-,
trazodone free base
BRD-K70778732-003-15-0
SDCCGSBI-0051126.P004
NCGC00016035-25
AMY32533
EN300-708789
CS-0009580
HY-B0478A
trazodona (inn-spanish)
2-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)(1,2,4)triazolo(4,3-a)pyridin-3(2h)-one
trazodonum (inn-latin)
2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)(1,2,4)triazolo(4,3-a)pyridin-3(2h)-one
n06ax05
trazodonum (latin)
dtxcid3025043

Research Excerpts

Overview

Trazodone (TZD) is a tetracyclic serotonin antagonist and reuptake inhibitor. It is used as a second-generation phenylpiperazine antidepressant. The drug has complex agonistic/antagonistic effects on the serotonergic system and moderate blockage on the histamine receptor.

ExcerptReferenceRelevance
"Trazodone (TZD) is a tetracyclic serotonin antagonist and reuptake inhibitor that is used as a second-generation phenylpiperazine antidepressant. "( Development of a Novel Analytical Method for Determining Trazodone in Human Plasma by Liquid Chromatography Coupled With Mass Spectrometry Coupled With Automatic 2-Dimensional Liquid Chromatograph-Mass Spectrometer Coupler 9500 and Its Application to Ther
Cui, X; Ding, J; Zhang, S; Zhang, Y; Zhao, C, 2022
)
2.41
"Trazodone is a frequently used antidepressant with complex agonistic/antagonistic effects on the serotonergic system and moderate blockage on the histamine receptor."( Restless Legs Syndrome Due to the Use of Trazodone: A Case Report.
Yilbaş, B, 2022
)
1.71
"Trazodone (TZD) is an antidepressant drug consumed worldwide since the 1970s."( Electropolymerized, Molecularly Imprinted Polymer on a Screen-Printed Electrode-A Simple, Fast, and Disposable Voltammetric Sensor for Trazodone.
Delerue-Matos, C; Pacheco, JG; Rebelo, P; Seguro, I, 2022
)
1.65
"Trazodone is an anxiolytic used PO to decrease anxiety in dogs. "( Effects of trazodone administration on the neurologic examination in healthy dogs.
Cameron, S; Lueck, LC; Zidan, N, 2022
)
2.55
"Trazodone hydrochloride is an antidepressant medicine that affects the chemical messengers in the brain known as neurotransmitters, which include acetylcholine, norepinephrine, dopamine, and serotonin."( Attempting to Increase the Effectiveness of the Antidepressant Trazodone Hydrochloride Drug Using π-Acceptors.
Alamri, A; Alamri, AS; Alhabeeb, AA; Alhomrani, M; Alkhatabi, HA; Alsanie, WF; Alyami, H; Felimban, RI; Gaber, A; Habeeballah, H; Raafat, BM; Refat, MS; Shakya, S, 2022
)
1.68
"Trazodone hydrochloride is an antidepressant used in clinical practice. "( Influence of Genetic Polymorphisms on the Pharmacokinetics of Trazodone Hydrochloride: A Scoping Review and Future Perspective.
Meulman, J; Moriel, P; Pincinato, EC; Visacri, MB, 2023
)
2.59
"Trazodone is an efficacious atypical antidepressant acting both as an SSRI and a 5HT2A and 5HT2C antagonist. "( Chronic Trazodone and Citalopram Treatments Increase Trophic Factor and Circadian Rhythm Gene Expression in Rat Brain Regions Relevant for Antidepressant Efficacy.
Candeletti, S; Caputi, FF; Carboni, L; Romualdi, P; Rullo, L; Stamatakos, S, 2022
)
2.6
"Trazodone is a selective serotonin reuptake inhibitor; however, other mechanisms of the drug's anti-depressive properties have also been postulated. "( Biochemical and Biophysical in Vitro Studies and Systematic Literature Review on the Antioxidant and Antiglycation Activities of Trazodone.
Maciejczyk, M; Nesterowicz, M; Zalewska, A; Żendzian-Piotrowska, M; Ładny, JR, 2023
)
2.56
"Trazodone is an approved antidepressant drug for adults and has shown efficacy on symptoms like anxiety and insomnia observed in AUD patients as well."( Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone.
Di Nicola, M; Janiri, L; Moccia, L; Panaccione, I; Pepe, M; Sani, G, 2023
)
1.84
"Trazodone is a serotonin reuptake inhibitor and a 5-HT2 receptor antagonist: it is effective in the treatment of the frontal syndrome and is commonly used in frontotemporal degeneration."( [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies].
Blanc, F; Javelot, H; Merignac, J; Moog, C; Muller, C; Schorr, B, 2023
)
1.97
"Trazodone is an antidepressant acting primarily due to the blockade of postsynaptic serotonin 5H2A- and 5H2C-receptors, as well as the blockade of serotonin reuptake, but also has affinity for a number of additional receptors."( [Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone].
Iuzbashian, PG; Romanov, DV; Samsonova, MD, 2023
)
1.84
"Trazodone is a serotonin antagonist/reuptake inhibitor medication commonly used for anxiety in dogs. "( Adverse effects of trazodone in dogs on primary hemostasis and electrocardiogram: A single-blinded placebo-controlled crossover study.
Baumwart, R; Benjamin, EJ; Haines, J; Nelson, OL,
)
1.9
"Trazodone is an antidepressant drug with considerable affinity for 5-HT1A receptors and α1-adrenoceptors for which the drug is competitive agonist and antagonist, respectively. "( Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and α1-adrenoceptor antagonism.
Bonfiglio, F; Corradetti, R; Magnani, M; Mlinar, B; Montalbano, A; Polenzani, L, 2019
)
2.26
"Trazodone (TRZ) is a compound with a multi-modal mechanism of action, being a serotonin-2 antagonist/reuptake inhibitor developed and approved for the treatment of depression in several countries."( Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study.
Calisti, F; Cattaneo, A; Comandini, A; Cruccu, G; Del Vecchio, A; Di Loreto, G; Ehler, E; Lipone, P; Nastaj, M; Palka-Kisielowska, I; Pochiero, I; Truini, A, 2020
)
1.55
"Trazodone is a multifunctional drug, characterized by different affinities for specific receptors and transporters. "( [Personalized medicine with extended-release trazodone and/or once-a-day trazodone: from research trials to clinical practice].
Cuomo, A; Fagiolini, A; Fiorentini, A; Vampini, C,
)
1.83
"Trazodone is an effective medication for patients with MDD and insomnia."( [Personalized treatment of depression phenotypes: role of trazodone in depression with insomnia].
Antonelli Incalzi, R; Caraci, F; Cuomo, A; Fagiolini, A; Ferini Strambi, L,
)
1.82
"Trazodone (TRZ) is a commonly prescribed antidepressant with significant off-label use for insomnia. "( Trazodone effects on developing brain.
Allen, LB; Anderson, A; Genaro-Mattos, TC; Korade, Z; Mirnics, K; Porter, NA; Tallman, KA, 2021
)
3.51
"Trazodone is a serotonin antagonist and reuptake inhibitor approved for the treatment of major depressive disorder."( Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action.
Albert, U; Lamba, P; Stahl, SM, 2021
)
1.68
"Trazodone is a widely used antidepressant that is also useful in the control of agitation and insomnia in Alzheimer's disease. "( The effects of trazodone on human cognition: a systematic review.
Gonçalo, AMG; Vieira-Coelho, MA, 2021
)
2.42
"Trazodone is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of depression and insomnia. "( Fatal Cerebral Edema, Seizures, and Hyponatremia After Trazodone Overdose.
Avila, JD,
)
1.82
"Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson's disease (PD). "( Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG, 2018
)
3.37
"Trazodone is a drug that was introduced in the clinic almost 40 years ago. "( Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets.
Settimo, L; Taylor, D, 2018
)
2.17
"Trazodone is a serotonin receptor antagonist and reuptake inhibitor used extensively as an anxiolytic in human and small animal veterinary medicine. "( Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse.
Davis, JL; Medlin, E; Schirmer, J, 2018
)
2.17
"Trazodone (TRZ) is an antidepressant drug commonly used in the treatment of depression, anxiety, and insomnia. "( Assessment of trazodone-induced cardiotoxicity after repeated doses in rats.
Atli, O; Baysal, M; Gormus, G; Ilgin, S; Kilic, G; Kilic, V; Korkut, B; Ucarcan, S, 2019
)
2.32
"Trazodone is an atypical antidepressant with no established safety in children. "( Unintentional trazodone overdoses in children ≤6 years of age: data from poison center over a period of 16 years.
El Zahran, T; Geller, RJ; Herrington, L; Hon, S; Morgan, BW, 2019
)
2.32
"Trazodone is a multifunctional triazolopyridine drug with antidepressant, anxiolytic, sedative, and hypnotic properties. "( Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder.
Ballerio, M; Crapanzano, C; Cuomo, A; Emanuele, E; Fagiolini, A; Goracci, A; Politi, P, 2018
)
2.2
"Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. "( Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.
Ballerini, A; Bruni, AC; Cuomo, A; Decina, P; Di Sciascio, G; Fagiolini, A; Fiorentini, A; Scaglione, F; Vampini, C,
)
1.86
"Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. "( Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.
Ballerini, A; Bruni, AC; Cuomo, A; Decina, P; Di Sciascio, G; Fagiolini, A; Fiorentini, A; Scaglione, F; Vampini, C,
)
1.86
"Trazodone is a second-generation antidepressant approved by the U.S."( A nationwide population study of trazodone use in urology patients.
Chen, KK; Chen, TJ; Cheng, WM; Lin, AT; Lin, TP, 2013
)
1.39
"Trazodone (TDZ) is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors."( Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NF-κB, p38 and JNK.
Da Pozzo, E; Daniele, S; Martini, C; Zappelli, E, 2015
)
2.58
"Trazodone is a heterocyclic antidepressant that exerts its effect via the inhibition of selective serotonin reuptake and the antagonism of 5-HT2A and 5-HT2C receptors. "( Trazodone induced galactorrhea: a case report.
Arslan, FC; Ozkorumak, E; Tiryaki, A; Uysal, EK,
)
3.02
"Trazodone is a second-generation atypical antidepressant exercising selective inhibitory action on the transport of serotonin. "( Trazodone in the elderly: risk of extrapyramidal acute events.
Esperança, S; Oliveira e Silva, A; Pacheco, AP; Sotto Mayor, J, 2015
)
3.3
"Trazodone (TDZ) is a triazolopyridine derivative that is structurally unrelated to other major classes of antidepressants."( Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes.
Daniele, S; Martini, C; Zappelli, E, 2015
)
2.58
"Trazodone is an effective antidepressant. "( Efficacy and tolerability of trazodone retard monotherapy: results of the Serbian non-interventional study.
Lečić-Toševski, D; Miljevic, CD, 2016
)
2.17
"Trazodone contramid is a relatively new formulation of trazodone, which has proven effective in MDD, particularly in those difficult to treat cases of MDD characterized by symptoms such as insomnia, anxiety, dementia or (ipo)manic symptoms. "( [Trazodone Contramid® in clinical practice: personalizing antidepressant intervention].
Amodeo, G; Blardi, P; Fagiolini, A; Goracci, A,
)
2.48
"Trazodone is an antidepressant that is FDA-approved for the treatment of depression. "( A review of trazodone use in psychiatric and medical conditions.
Khouzam, HR, 2017
)
2.28
"Trazodone is a commonly prescribed off-label for sleep disturbance in alcohol-dependent patients, but its safety and efficacy for this indication is unknown."( Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial.
Friedmann, PD; Millman, RP; Rose, JS; Stein, MD; Stout, RL; Swift, R, 2008
)
3.23
"Trazodone is an sedative antidepressant, acting quickly, efficiently, safely, with a small number of adverse reactions and proven effective in the treatment of insomnia."( [Efficacy of trazodone in the treatment of insomnia].
Florkowski, A; Gałecki, P; Talarowska, M, 2010
)
1.45
"Trazodone (Trz) is an antidepressant agent demonstrating prominent serotonergic antagonistic properties."( Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study.
Bar, F; Rosenzcwaig, S; Spivak, B; Stryjer, R; Ulman, AM; Weizman, A,
)
2.3
"Trazodone is an antidepressant of the serotonin (5-HT2) antagonist and reuptake inhibitor class, and has been considered to act as a multifunctional drug. "( [Trazodone--its multifunctional mechanism of action and clinical use].
Frecska, E, 2010
)
2.71
"Trazodone is an established antidepressant that is prescribed frequently as an off-label hypnotic with wide acceptance among psychiatrists. "( Trazodone: properties and utility in multiple disorders.
Mittur, A, 2011
)
3.25
"Trazodone is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. "( Off-label uses of trazodone: a review.
Bossini, L; Casolaro, I; Cecchini, F; Fagiolini, A; Koukouna, D, 2012
)
2.16
"Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). "( Rediscovering trazodone for the treatment of major depressive disorder.
Catena Dell'Osso, M; Comandini, A; Fagiolini, A; Kasper, S, 2012
)
2.18
"Trazodone is an antidepressant agent demonstrating prominent serotonergic antagonistic properties."( Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone.
Bar, F; Kotler, M; Poyurovsky, M; Strous, RD; Stryjer, R; Weizman, A,
)
1.09
"Trazodone is an atypical antidepressant that is commonly used in the treatment of affective disorders. "( Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.
Bloehs, R; Karle, CA; Kathöfer, S; Katus, HA; Kiehn, J; Kiesecker, C; Kreye, VA; Lück, S; Schoels, W; Scholz, E; Thomas, D; Zitron, E, 2004
)
2
"Trazodone is a psychoactive compound with sedative and antidepressant properties, and with mixed serotonin agonist and antagonist effects."( Trazodone for agitation in dementia.
Fioravanti, M; Grimley, EJ; Martinon-Torres, G, 2004
)
2.49
"Trazodone is an effective antidepressant drug with a broad therapeutic spectrum, including anxiolytic efficacy. "( Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding.
Odagaki, Y; Toyoshima, R; Yamauchi, T, 2005
)
3.21
"Trazodone is an antidepressant agent used in Spain since 1975. "( Investigation of a fatality due to trazodone poisoning: case report and literature review.
Almarza, E; Ballesteros, S; Martínez, MA; Sánchez de la Torre, C,
)
1.85
"(1). Trazodone turned out to be an efficacious medicine in the therapy of adjustment disorders. "( [The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research].
Florkowski, A; Gałecki, P; Zboralski, K, 2005
)
1.14
"Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters."( Does trazodone have a role in palliating symptoms?
Davis, MP, 2007
)
2.3
"Trazodone is a second-generation antidepressant with serotonin antagonist activity."( HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma.
Amore, M; Colliva, C; Fanali, S; Mercolini, L; Raggi, MA, 2008
)
1.34
"Trazodone is a new psychotropic drug which has a marked norepinephrine receptor blocking power; moreover, it inhibits serotonin reuptake and was fully effective in the treatment of man's withdrawal syndrome (17 alcoholic inpatients)."( Alcohol withdrawal syndrome: treatment with trazodone.
Albano, C; Farelli, S; Maffini, M; Roccatagliata, G, 1980
)
1.24
"Trazodone is a new antidepressant agent that was recently introduced in the United States. "( Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology.
Forsell, TL; Georgotas, A; Gershon, S; Kim, M; Mann, JJ,
)
3.02
"Trazodone is an effective antidepressant with a low incidence of serious adverse effects."( Antidepressant properties of trazodone.
Bryant, SG; Ereshefsky, L,
)
1.14
"Trazodone is a triazolopyridine derivative with antidepressant activity, that is chemically unrelated to other currently available antidepressants. "( Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1981
)
3.15
"Trazodone is a sedating antidepressant without anticholinergic properties."( The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects.
McBrayer, RH; Rose, FV; Ware, JC, 1994
)
1.29
"Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia."( Trazodone for antidepressant-associated insomnia.
Adler, LA; Nierenberg, AA; Peselow, E; Rosenthal, M; Zornberg, G, 1994
)
3.17
"Trazodone is a triazolopyridine derivative, chemically and pharmacologically unrelated to other currently available antidepressants. "( Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
Fitton, A; Haria, M; McTavish, D, 1994
)
3.17
"Trazodone is a drug that acts a weak, but specific, inhibitor of the uptake of 3H-serotonin and is generally used for its antidepressant effects."( Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms.
Albertazzi, P; Bonaccorsi, G; Campobasso, C; Dossi, L; Mollica, G; Pansini, F; Porto, S; Zanotti, L, 1995
)
2.46
"Trazodone (Desyrel) is a second-generation, nontricyclic antidepressant that has been in use in North America since the early 1980s. "( Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity.
Fernandes, NF; Martin, RR; Schenker, S, 2000
)
3.19
"Trazodone is a non-tricyclic antidepressant drug with specific antagonistic activities at 5-HT(2) and alpha-1 adrenoceptors. "( Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study.
Conte, G; De Risio, S; Pozzi, G, 2000
)
2.1
"Trazodone is a popular antidepressant medication that has been available for approximately 30 years. "( Postmortem forensic toxicology of trazodone.
Goeringer, KE; Logan, BK; Raymon, L, 2000
)
2.03
"Trazodone is a psychotropic drug with a clinically proven antidepressant activity."( Comparative cardiovascular toxicity of trazodone and imipramine in the rat.
Campana, A; Lisciani, R; Scorza Barcellona, P, 1978
)
1.25
"Trazodone is an atypical antidepressant drug that is commonly referred to as a serotonin (5-hydroxytryptamine; 5-HT) uptake inhibitor. "( A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action.
Marek, GJ; McDougle, CJ; Price, LH; Seiden, LS, 1992
)
2.07
"Trazodone is a structurally unique bicyclic anti-depressant, said to be significantly less toxic than other anti-depressants following an acute overdose. "( Post-mortem toxico-kinetics of trazodone.
Martin, A; Pounder, DJ, 1992
)
2.01
"Trazodone is a novel antidepressant drug with alpha-adrenolytic activity. "( Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels.
Monteleone, P, 1991
)
2.11
"Trazodone hydrochloride is an oral antidepressant agent which has been associated with the improvement of erections in impotent men and the development of prolonged erections or priapism in potent men. "( Effects of intracavernosal trazodone hydrochloride: animal and human studies.
Azadzoi, KM; Goldstein, I; Krane, RJ; Payton, T, 1990
)
2.02
"Trazodone is an atypical antidepressant drug (i.e. "( Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine.
Hand, TH; Li, AA; Marek, GJ; Seiden, LS, 1990
)
2.01
"Trazodone (Desyrel) is a good antidepressant for the elderly because of its minimal anticholinergic effects, although it is quite sedating."( Psychotropic drugs in the elderly. Selection of the appropriate agent.
Barclay, AM, 1985
)
0.99
"Trazodone hydrochloride is a potent presynaptic serotonin reuptake blocker with few anticholinergic and cardiovascular side effects."( Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study.
Davidoff, G; Guarracini, M; Roth, E; Sliwa, J; Yarkony, G, 1987
)
2.44
"Trazodone is an atypical antidepressant with additional anxiolytic effects. "( Recent experience with trazodone.
Lader, M, 1987
)
2.03
"Trazodone is a molecule which is already well known throughout the world for its antidepressant properties and its good global safety. "( [Telematic multicenter study of Pragmarel 100 mg (trazodone)].
Benkelfat, C; Gay, C; Renardet, M, 1986
)
1.97
"Trazodone is a selective serotonergic agent with low anticholinergic activity, and minimal morbidity/mortality in overdose."( Second generation antidepressants: a comparative review.
Coccaro, EF; Siever, LJ,
)
0.85

Effects

Trazodone hydrochloride has a short half-life compared with other commercially available antidepressants. It is a potent serotonin 5-HT2A and α1-adrenergic receptor antagonist, and weak antihistamine or histamine H1 receptor inverse agonist.

Trazodone has minimal effect on cardiac conduction. Main cardiovascular effects are hypotension, orthostasis, and dizziness. Side effect profile is mild, with sedation the most common side effect.

ExcerptReferenceRelevance
"Trazodone has a variety of effects on several monoaminergic mechanisms: a potent serotonin 5-HT2A and α1-adrenergic receptor antagonist, a weak serotonin reuptake inhibitor, and a weak antihistamine or histamine H1 receptor inverse agonist."( Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions.
Ashford, JW, 2019
)
1.51
"Trazodone has a unique pharmacology, which may be an advantage in palliating symptoms; however, little evidence is available through cohort or randomized trials to give guidance to its use."( Does trazodone have a role in palliating symptoms?
Davis, MP, 2007
)
2.3
"Trazodone hydrochloride has a short half-life compared with other commercially available antidepressants."( A possible diurnal variation in trazodone clearance.
Baxter, LR; Smith, GB; Wilkins, JN, 1986
)
1.28
"Trazodone has been recently found to inhibit 7-dehydrocholesterol reductase and alter sterol concentrations in rodents, cell culture, human fibroblasts, and blood."( Desmosterol and 7-dehydrocholesterol concentrations in post mortem brains of depressed people: The role of trazodone.
Brown, ES; Cenik, B; Cenik, C; McDonald, JG; Palka, JM; Tamminga, CA; Thompson, BM, 2022
)
1.66
"Trazodone has been widely prescribed for off-label use as a sleep aid. "( Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis.
Lv, T; Lyu, Y; Wu, J; Zheng, Y, 2022
)
3.61
"Trazodone has significant hypnotic and anxiolytic properties, which gives it special meaning in the treatment of depression, combined with insomnia and anxiety."( [Serotonin neurotrasmission and treatment options for depression].
Sivolap, YP,
)
0.85
"Trazodone has a variety of effects on several monoaminergic mechanisms: a potent serotonin 5-HT2A and α1-adrenergic receptor antagonist, a weak serotonin reuptake inhibitor, and a weak antihistamine or histamine H1 receptor inverse agonist."( Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions.
Ashford, JW, 2019
)
1.51
"Trazodone has proven an effective medication in patients with MDD but has not been extensily studied in terms of its efficacy for specific phenotypes of depression. "( [Trazodone Contramid® in clinical practice: personalizing antidepressant intervention].
Amodeo, G; Blardi, P; Fagiolini, A; Goracci, A,
)
2.48
"Trazodone has been shown to be a good option for treatment of the elderly with dementia and associated SD."( Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study.
Camargos, EF; Freitas, MP; Lima, Jde O; Medeiros-Souza, P; Miranda, LC; Pandolfi, MB; Pimentel, W; Quintas, JL, 2011
)
2.53
"Trazodone has the most data suggesting efficacy. "( Pharmacological treatment of insomnia in alcohol recovery: a systematic review.
Kolla, BP; Mansukhani, MP; Schneekloth, T,
)
1.57
"Trazodone has been reported to be an effective hypnotic for patients with antidepressant-associated insomnia."( The effects of trazodone on sleep in patients treated with stimulant antidepressants.
Gözükirmizi, E; Guilleminault, C; Kaynak, D; Kaynak, H, 2004
)
1.4
"Trazodone has been associated with prolonged QT-interval and increased risk of polymorphous ventricular tachycardias clinically and has demonstrated in vitro inhibition of hERG (human ether-á-go-go-related gene) channel current. "( Effect of trazodone on hERG channel current and QT-interval.
Appleton, N; Lansdell, K; Tarantino, P, 2005
)
2.17
"As trazodone has been implicated in cardiac disorders, a further search was conducted using the term cardiac and trazodone."( A review of the evidence for the efficacy and safety of trazodone in insomnia.
Mendelson, WB, 2005
)
1.09
"Trazodone has a unique pharmacology, which may be an advantage in palliating symptoms; however, little evidence is available through cohort or randomized trials to give guidance to its use."( Does trazodone have a role in palliating symptoms?
Davis, MP, 2007
)
2.3
"Trazodone also has interactions with warfarin through not well-understood mechanisms."( Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids.
Dehpour, AR; Jalili, M, 2007
)
1.29
"Trazodone has biphasic elimination, with a redistribution half-life of about one hour and an elimination half-life of 10-12 hours."( Antidepressant properties of trazodone.
Bryant, SG; Ereshefsky, L,
)
1.14
"Trazodone has been reported to be of value in tremors and chronic alcoholism."( Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1981
)
2.43
"Trazodone has been used successfully to relieve depression in schizophrenic patients without worsening their psychotic symptoms."( Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division).
Rawls, WN, 1982
)
2.43
"Trazodone has also been successfully used in a small number of patients with depression and pre-existing cardiovascular disease."( Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
Fitton, A; Haria, M; McTavish, D, 1994
)
2.45
"Trazodone has high and moderate affinity for human alpha1- and alpha2-adrenoceptors, respectively; this might contribute to its reported beneficial effects in erectile dysfunction."( Affinity of trazodone for human penile alpha1- andalpha2-adrenoceptors.
Goepel, M; Krege, S; Michel, MC; Sperling, H, 2000
)
2.13
"Trazodone has been used widely to treat insomnia in depressed patients. "( Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia.
Hanson, CA; Krahn, LE; Pileggi, TS; Rummans, TA, 2001
)
1.98
"Trazodone has been reported to be both an effective nonbenzodiazepine hypnotic for antidepressant-associated insomnia and a possible serotonergic antidepressant adjunct."( Possible trazodone potentiation of fluoxetine: a case series.
Cole, JO; Glass, L; Nierenberg, AA, 1992
)
1.42
"Trazodone has been shown to be safe in overdose, and the side effect profile is mild, with sedation the most common side effect."( Trazodone dosing regimen: experience with single daily administration.
Fabre, LF, 1990
)
2.44
"Trazodone has minimal effect on cardiac conduction; its main cardiovascular effects are hypotension, orthostasis, and dizziness."( Adverse reactions to five new antidepressants.
Hayes, PE; Kristoff, CA, 1986
)
0.99
"Trazodone has been shown to be at least as effective as standard antidepressants."( Overview of USA controlled trials of trazodone in clinical depression.
Boyer, WF; Feighner, JP, 1988
)
1.27
"Trazodone has become a very popular second generation antidepressant. "( A retrospective evaluation of plasma trazodone concentrations and clinical response in a primary care clinic.
Garvey, MJ; Luxenberg, M; Saxena, S; Tollefson, GD, 1988
)
1.99
"Trazodone has emerged as the antidepressant drug with the least risk of death in overdose, and as a useful alternative to the standard tricyclic antidepressant drugs in patients with preexisting conduction disease."( Cardiovascular toxicity of antidepressant medications.
Glassman, AH; Jackson, WK; Roose, SP, 1987
)
0.99
"Trazodone has been shown to demonstrate comparable efficacy to the other reuptake and monoamine oxidase inhibitors, but has the advantages of a low cardiovascular-risk profile, extremely low suicide toxicity, absence of anticholinergic side effects, and minimal effects on cognition."( Geriatric depression and treatment with trazodone.
Gerner, RH, 1987
)
1.26
"Trazodone hydrochloride has a short half-life compared with other commercially available antidepressants."( A possible diurnal variation in trazodone clearance.
Baxter, LR; Smith, GB; Wilkins, JN, 1986
)
1.28
"Trazodone has been approved for marketing in the United States over three years ago. "( [Tolerance and pharmacovigilance of trazodone].
Aleem, A; Gershon, S; Yeragani, VK, 1986
)
1.99

Actions

Trazodone tends to inhibit biochemical and pharmacological functions depending on the catecholaminergic system, whereas imipramine has a potentiating activity. Trazodon 100 mg may cause cognitive driving impairment.

ExcerptReferenceRelevance
"Trazodone 100 mg may cause cognitive driving impairment."( The effect of trazodone on standardized field sobriety tests.
Barnett, MJ; Bui, QV; Ip, EJ; Kazani, A; Perry, PJ; Serino, MJ; Wright, R, 2013
)
1.47
"Trazodone caused an increase in reactive oxygen species (ROS) formation, malondialdehyde accumulation, depletion of intracellular reduced glutathione (GSH), rise of oxidized glutathione disulfide (GSSG), and a decrease in mitochondrial membrane potential, which confirms the role of oxidative stress in trazodone-induced cytotoxicity."( Mechanisms of trazodone-induced cytotoxicity and the protective effects of melatonin and/or taurine toward freshly isolated rat hepatocytes.
Eghbal, MA; Sattari, MR; Taziki, S, 2013
)
1.47
"Trazodone may increase arousal threshold without compromising upper airway muscles, which should improve OSA."( Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold.
Deyoung, PN; Edwards, BA; Malhotra, A; McSharry, DG; Orr, JE; Owens, R; Smales, ET; Velasquez, A; Wellman, A, 2015
)
2.58
"So, trazodone appears to produce a stabilization of the circadian rhythms in individuals with AD."( Circadian rhythm in Alzheimer disease after trazodone use.
Camargos, EF; Gonçalves, BS; Grippe, TC; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2015
)
1.16
"Trazodone tends to inhibit biochemical and pharmacological functions depending on the catecholaminergic system, whereas imipramine has a potentiating activity."( Trazodone, a new avenue in the treatment of depression.
Silvestrini, B; Valeri, P, 1984
)
2.43
"Trazodone appears to produce less cardiovascular toxicity than tricyclic antidepressants."( Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division).
Rawls, WN, 1982
)
2.43

Treatment

Treatment with trazodone and imipramine significantly improved locomotor activity and exerted anxiolytic-like effects in all paradigm tasks (mirror chamber, elevated plus maze, zero maze) as compared to untreated 72-h sleep-deprived animals (P < 0.05) Treatment with traZodone or nefazodone caused a dose-dependent decrease in serum nitric oxide levels compared with CCl(4) control group.

ExcerptReferenceRelevance
"Dogs treated with trazodone versus placebo had lower mean DSSs, assessed by owners for physical examination and assessed by video analysis for time spent in the examination room; lower mean SD of normal-to-normal intervals, root mean square of successive heartbeat interval difference, and respiratory rate; and higher mean heart rate. "( Effects of trazodone on behavioral and physiological signs of stress in dogs during veterinary visits: a randomized double-blind placebo-controlled crossover clinical trial.
Bain, MJ; Borchardt, MR; Kim, SA; Lee, K; Stelow, EA, 2022
)
1.45
"Treatment with trazodone and imipramine significantly improved locomotor activity and exerted anxiolytic-like effects in all paradigm tasks (mirror chamber, elevated plus maze, zero maze) as compared to untreated 72-h sleep-deprived animals (P < 0.05)."( Possible role of trazodone and imipramine in sleep deprivation-induced anxiety-like behavior and oxidative damage in mice.
Garg, R; Kumar, A,
)
0.81
"Pretreatment with trazodone and citalopram significantly reversed immobilized stress-induced behavioral and biochemical alterations."( Possible role of NO modulators in protective effect of trazodone and citalopram (antidepressants) in acute immobilization stress in mice.
Garg, R; Gaur, V; Kumar, A; Kumar, P, 2010
)
0.93
"Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain. "( Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study.
Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011
)
2.16
"Treatment with trazodone or nefazodone caused a dose-dependent decrease in serum nitric oxide levels compared with the CCl(4) control group."( Effect of trazodone and nefazodone on hepatic injury induced by carbon tetrachloride.
Abdel Salam, OM; Shafee, N; Sleem, AA, 2010
)
1.1
"The treatment with trazodone decreased the score in the AIS (13.5 +/- 2.4 vs. "( [The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use].
Czasak, K; Jernajczyk, W; Musińska, I; Sobańska, A; Szatkowska, E; Wichniak, A; Wierzbicka, A, 2007
)
0.94
"Treatment with trazodone promises less risks according to the clinical experience described in the international literature."( Experiences with doxepin and trazodone in the therapy with outpatients suffering from depression.
Pöldinger, W, 1984
)
0.9
"Pretreatment with trazodone does not modify TRH-induced PRL release."( Effect of a psychoactive drug, trazodone, on prolactin secretion in man.
Barreca, T; Magnani, G; Milesi, GM; Rolandi, E, 1981
)
0.87

Toxicity

Trezodone is relatively safe when taken in overdose. No deaths have been reported to the manufacturer when trazodone was the only agent taken.

ExcerptReferenceRelevance
" Frequently encountered adverse effects are emphasized, but some of the more serious rare ones are also considered."( Antidepressant drug side effects.
Bodkin, JA; Cole, JO, 1990
)
0.28
" Since tricyclic antidepressants and lithium are the most commonly used psychotropic drugs in the treatment of depression, their side effects and adverse reactions are discussed specifically as these relate to the elderly."( Antidepressant drug therapy in the elderly: enhancing safety and compliance.
Halaris, A,
)
0.13
" In contrast, trazodone is relatively safe when taken in overdose; no deaths have been reported to the manufacturer when trazodone was the only agent taken."( The greater safety of trazodone over tricyclic antidepressant agents: 5-year experience in the United States.
Rakel, RE, 1987
)
0.95
" However, trazodone therapy has been associated with some adverse effects, and, therefore, from the data presented in this paper, it can be concluded that no drug currently available is without some cardiovascular risk."( Cardiovascular toxicity of antidepressant medications.
Glassman, AH; Jackson, WK; Roose, SP, 1987
)
0.68
" However, the laboratory pharmacological characteristics of agents are a more reliable predictor of side effect profiles than they are of their therapeutic activities."( Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population.
Gershon, S, 1984
)
0.54
"Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects."( The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Dording, CM; Fava, M; Gordon, J; Kornbluh, R; Mischoulon, D; Nierenberg, AA; Petersen, TJ; Rosenbaum, JE, 2002
)
0.31
" Thus short-term low-dose administration of ritonavir impairs oral clearance of trazodone and increases the occurrence of adverse reactions."( Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.
Byron, S; Chen, G; Culm, KE; Daily, JP; Fogelman, SM; Graf, JA; Granda, BW; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL, 2003
)
0.77
" In addition, commonly used texts were consulted for information regarding adverse effects related to trazodone."( A review of the evidence for the efficacy and safety of trazodone in insomnia.
Mendelson, WB, 2005
)
0.79
"Given the relative absence of efficacy data in patients with insomnia and the adverse events associated with trazodone's use in general, it is uncertain whether the risk/benefit ratio warrants trazodone's use in nondepressed patients with insomnia."( A review of the evidence for the efficacy and safety of trazodone in insomnia.
Mendelson, WB, 2005
)
0.79
" One rare but serious side effect of the drug is priapism, the urological emergency in which the cavernosa of the penis become painfully engorged in the absence of sexual stimulation."( Safety of trazodone as a sleep agent for inpatients.
Jayaram, G; Rao, P,
)
0.53
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Clinicians should select antidepressants considering their pharmacologic profiles and avoiding adverse effects."( [Review of pharmacological efficacies and side effects of antidepressants].
Ikenouchi-Sugita, A; Nakamura, J; Yoshimura, R, 2007
)
0.34
" In accord with its clinical disposition, nefazodone was the most toxic compound of the three, trazodone had relatively modest effects, whereas buspirone showed the least toxicity."( In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone.
Dunn, MC; Dykens, JA; Jamieson, JD; Marroquin, LD; Nadanaciva, S; Smith, AR; Will, Y; Xu, JJ, 2008
)
0.79
" Some animal studies indicate that such nanomaterials may have some toxicity, but their synergistic actions on the adverse effects of drugs are not well understood."( Effect of 70-nm silica particles on the toxicity of acetaminophen, tetracycline, trazodone, and 5-aminosalicylic acid in mice.
Hasezaki, T; Isoda, K; Kondoh, M; Li, X; Tsutsumi, Y; Watari, A; Yagi, K, 2011
)
0.6
" There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events."( A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C, 2011
)
0.58
" Karachi, to evaluate the efficacy and adverse effects in major depressive disorder individuals."( Assessment of efficacy and adverse effects of trazodone in the treatment of major depressive disorder.
Das, D; Khan, M; Sarwar, G; Tunio, AG,
)
0.39
" Administration of melatonin reduced the toxic effects of trazodone in isolated rat hepatocytes."( Mechanisms of trazodone-induced cytotoxicity and the protective effects of melatonin and/or taurine toward freshly isolated rat hepatocytes.
Eghbal, MA; Sattari, MR; Taziki, S, 2013
)
0.99
" The majority of the adverse reactions of trazodone were mild to moderate, and the most frequent adverse reactions (≥5%) were dizziness, dry mouth, somnolence, and nausea."( Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.
Cao, Y; Chen, DC; Cheng, ZH; Cui, LJ; Li, LH; Shi, JG; Tan, QR; Wang, G; Xie, WW; Xu, XF; Zhang, HG; Zhang, KR; Zhang, L; Zhao, JP; Zheng, HB, 2014
)
0.93
" To elucidate the cellular mechanism for the adverse cardiac effects of trazodone, we investigated its effects on cardiac APs and ion channels using whole-cell patch clamp techniques in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and transiently transfected human embryonic kidney cells (HEK293) with cardiac ion channel complementary DNA."( Cellular mechanisms for trazodone-induced cardiotoxicity.
Kim, KS; Kim, SJ; Lee, HA; Lee, S, 2016
)
0.97
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
"The aim was to evaluate the effect of polymorphisms in metabolizing enzymes and transporters on the pharmacokinetics, pharmacodynamics and adverse effects of trazodone in healthy volunteers."( Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.
Abad-Santos, F; Belmonte, C; Cabaleiro, T; Derqui-Fernández, N; Ochoa, D; Ovejero-Benito, MC; Román, M; Saiz-Rodríguez, M; Talegón, M, 2017
)
0.98
" Subjects with adverse drug reactions had lower concentrations of trazodone suggesting its metabolite (m-chlorophenylpiperazine) could be responsible for these effects."( Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.
Abad-Santos, F; Belmonte, C; Cabaleiro, T; Derqui-Fernández, N; Ochoa, D; Ovejero-Benito, MC; Román, M; Saiz-Rodríguez, M; Talegón, M, 2017
)
1.02
" Although some studies demonstrated the adverse effects of TRZ related to cardiovascular system, the conflicting results were observed in these studies."( Assessment of trazodone-induced cardiotoxicity after repeated doses in rats.
Atli, O; Baysal, M; Gormus, G; Ilgin, S; Kilic, G; Kilic, V; Korkut, B; Ucarcan, S, 2019
)
0.87
" In our study, it was aimed to identify the possible toxic effects of trazodone on male rats and elucidate the underlying mechanisms."( Toxic Effects of Trazodone on Male Reproductive System via Disrupting Hypothalamic-Pituitary-Testicular Axis and Inducing Testicular Oxidative Stress.
Ardıç, M; Atlı, Ö; Aydoğan-Kılıç, G; Baysal, M; Ilgın, S; Kılıç, V; Uçarcan, Ş, 2018
)
1.05
" The most frequent adverse events (AEs) were dizziness and somnolence in the trazodone group, and nausea and headache in the venlafaxine group."( A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.
Albert, U; Cattaneo, A; Comandini, A; Di Dato, G; Di Loreto, G; Fagiolini, A; Ferrando, L; Herman, E; Kasper, S; Muntean, C; Olivieri, L; Pálová, E; Salvatori, E; Tongiani, S, 2020
)
1.02
" No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders."( Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study.
Calisti, F; Cattaneo, A; Comandini, A; Cruccu, G; Del Vecchio, A; Di Loreto, G; Ehler, E; Lipone, P; Nastaj, M; Palka-Kisielowska, I; Pochiero, I; Truini, A, 2020
)
0.83
" Veterinary professionals should be aware of the rare potential adverse effect that may be seen in canine patients secondary to trazodone therapy."( Suspected hepatotoxicity secondary to trazodone therapy in a dog.
Arnold, A; Davis, A; Lee, JA; Wismer, T, 2021
)
1.1
" Mild adverse events were reported in three patients in the clonazepam, two patients in the trazodone group, and none in the melatonin group."( Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial.
Agah, E; Aghamollaii, V; Hadi, F; Mirsepassi, Z; Mousavi, SV; Tafakhori, A; Talachi, N; Tavanbakhsh, S, 2022
)
1.19
" Side effects were measured with the Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU); the total score and UKU subscales were considered."( Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting.
De Ronchi, D; Fabbri, C; Ferentinos, P; Kasper, S; Mendlewicz, J; Montgomery, S; Panariello, F; Rujescu, D; Serretti, A; Souery, D; Zohar, J, 2023
)
0.91

Pharmacokinetics

The pharmacokinetic and pharmacodynamic characteristics of a controlled-release (CR) formulation of trazodone were evaluated in healthy subjects. TSR showed clear sustained-release characteristics, and food exhibited no significant effects on the pharmacokinetics parameters of traZodone. Age and sex had a significant influence on the Pharmacokinetic pattern of tra Zodone, causing higher concentrations in females and older patients.

ExcerptReferenceRelevance
"In a double-blind study, the pharmacodynamic effects of single and repeated doses of two formulations of trazodone were compared in 14 healthy young volunteers (6 men and 8 women)."( Trazodone conventional and controlled-release formulations: pharmacodynamic effects after single and repeated administration.
Ankier, SI; Debbas, NM; Warrington, SJ, 1989
)
1.93
"The pharmacokinetic and some pharmacodynamic characteristics of a single oral dose of 100 mg trazodone were compared in young and elderly volunteers."( Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly.
Ankier, SI; Bayer, AJ; Pathy, MS, 1983
)
0.73
" 2 Following oral administration of single 50 mg doses of two formulations of trazodone on separate occasions to healthy fasted volunteers, the peak plasma concentration, time to peak concentration, area under the curve, elimination rate constant and half-life were determined."( Trazodone--a new assay procedure and some pharmacokinetic parameters.
Ankier, SI; Carpenter, PK; Graham, C; Martin, BK; Rogers, MS, 1981
)
1.93
" The results indicate that neither the route of administration nor the dosage schedule affects in significant manner the pharmacokinetics of trazodone, but the pharmacokinetic parameters depend upon the dose used."( Pharmacokinetics of trazodone after different routes of administration.
Danek, L; Melzacka, M; Rurak, A, 1981
)
0.79
" The pharmacokinetic profile of CR trazodone, observed after 35 days of treatment, may account for both the low occurrence of untoward side effects and the therapeutic efficacy of the single dose at nighttime."( [Evaluation of therapeutic efficacy and pharmacokinetics of controlled release of trazodone in patients with major depressive disorder].
Delrio, G; Monteleone, P, 1994
)
0.79
"The pharmacokinetic and pharmacodynamic characteristics of a controlled-release (CR) formulation of trazodone were evaluated in healthy subjects who received acutely 150 mg and 75 mg of the CR trazodone and equal amounts of the conventional formulation on separate occasions."( Pharmacokinetic and pharmacodynamic characteristics of a controlled-release formulation of trazodone versus the conventional formulation in healthy volunteers.
Delrio, G; Monteleone, P, 1993
)
0.72
" These pharmacokinetic parameters did not differ significantly from those earlier reported in healthy subjects after a single dose administration of 100 mg when based on an oral availability of trazodone of 65%."( Pharmacokinetics of trazodone during multiple dosing to psychiatric patients.
Dale, O; Husebø, B; Nilsen, OG,
)
0.64
" There are substantial pharmacokinetic differences among the five major classes."( Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
Preskorn, SH, 1993
)
0.29
"A healthy 40-year-old Caucasian male volunteer displayed unusually low clearance and long elimination half-life of alprazolam and trazodone, two CYP3A substrate drugs, following single-dose oral administration in clinical pharmacokinetic studies."( Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region.
Cotreau, MM; Greenblatt, DJ; Tran, TH; von Moltke, LL, 2000
)
0.75
" The present results suggest that brain microdialysis methods may be applicable to pharmacokinetic and pharmacodynamic studies of psychotrophic agents."( Pharmacokinetic and pharmacodynamic analyses of trazodone in rat striatum by in vivo microdialysis.
Chen, CF; Cheng, FC; Kuo, JS; Tsai, TH; Wu, YS, 1999
)
0.56
"001), prolonged elimination half-life (6."( Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.
Byron, S; Chen, G; Culm, KE; Daily, JP; Fogelman, SM; Graf, JA; Granda, BW; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL, 2003
)
0.54
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" On the other hand, age and sex had a significant influence on the pharmacokinetic pattern of trazodone, causing higher concentrations in females and in older patients."( Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine?
Conca, A; König, P; Moll, W; Prapotnik, M; Waschgler, R, 2004
)
0.83
" The developed assay method was applied to a pharmacokinetic study after intravenous injection of apicidin in rats at a dose of 1 mg/kg."( Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study.
Han, JW; Kim, CH; Kim, J; Park, EH; Shin, BS; Yoo, SD; Yoon, CH, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"0g/kg silymarin significantly decreases trazodone's area under concentration curve (AUC), distribution half-life (t(1/2,alpha)), elimination half-life (t(1/2,beta)), and mean residence time (MRT)."( Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats.
Chang, JC; Lee, WC; Lin, LC; Tsai, TH; Wu, YT, 2009
)
0.85
" Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84."( Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs.
Benson, L; Jay, AR; Kravitz, A; Krotscheck, U; Mohammed, H; Mulligan, A; Parsley, E; Schwark, WS; Silva, J, 2013
)
0.63
" This validated method was successfully applied to a pharmacokinetic study enrolling 12 Chinese volunteers administered a single oral trazodone hydrochloride extended-release tablet of 75mg."( Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers.
Feng, W; Huan-De, L; Jiang, L; Li-Bo, D; Ping-Fei, F; Rong-Hua, Z, 2014
)
0.91
"Volume of distribution is one of the most important pharmacokinetic properties of a drug candidate."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" Samples were analyzed for trazodone and metabolite concentrations, and pharmacokinetic parameters were determined; plasma drug concentrations following IV administration best fit a 3-compartment model."( Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training.
Kass, PH; Knych, HK; Mama, KR; Stanley, SD; Steffey, EP, 2017
)
1.01
" Noncompartmental pharmacokinetic analysis, sedation and ataxia scores were determined."( Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse.
Davis, JL; Medlin, E; Schirmer, J, 2018
)
0.73
" Pharmacokinetic parameters were calculated by noncompartmental analysis."( Determination of the pharmacokinetics of a single oral dose of trazodone and its effect on the activity level of domestic pigeons (Columba livia).
Beaudry, F; Desmarchelier, MR; Ferrell, ST; Frank, D, 2019
)
0.75
" A validated high-performance liquid chromatography-fluorescence method was used to measure the plasma concentration of trazodone, and a non-compartment model was used to obtain the pharmacokinetic parameters."( Pharmacokinetics of trazodone sustained-release tablets in healthy subjects: Three open-label, randomized crossover studies
.
Gong, Y; Luo, WW; Peng, WX; Zhang, QZ; Zhu, JL; Zhu, RH, 2019
)
1.05
" In the food-drug interaction study, no significant changes in the pharmacokinetic parameters of the drug under the fed conditions were observed."( Pharmacokinetics of trazodone sustained-release tablets in healthy subjects: Three open-label, randomized crossover studies
.
Gong, Y; Luo, WW; Peng, WX; Zhang, QZ; Zhu, JL; Zhu, RH, 2019
)
0.84
"TSR showed clear sustained-release characteristics, and food exhibited no significant effects on the pharmacokinetic parameters of trazodone."( Pharmacokinetics of trazodone sustained-release tablets in healthy subjects: Three open-label, randomized crossover studies
.
Gong, Y; Luo, WW; Peng, WX; Zhang, QZ; Zhu, JL; Zhu, RH, 2019
)
1.04
" Pharmacokinetic parameters were estimated by noncompartmental analysis."( Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs.
Istvan, SA; Karriker, MJ; O'Donnell, EM; Press, SA, 2020
)
0.84
" Serum pioglitazone concentration was estimated by high performance liquid chromatography method for pharmacokinetic data."( Influence of trazodone on the pharmacodynamics and pharmacokinetics of pioglitazone.
Ahad, A; Chinthaginjala, H; Goruntla, N; Pradeepkumar, B; Raghavendra, M; Reddy, KS; Sudheer, A,
)
0.5
"Trazodone apparently produced pharmacokinetic interaction with pioglitazone which might be by attenuating the metabolism of pioglitazone."( Influence of trazodone on the pharmacodynamics and pharmacokinetics of pioglitazone.
Ahad, A; Chinthaginjala, H; Goruntla, N; Pradeepkumar, B; Raghavendra, M; Reddy, KS; Sudheer, A,
)
1.94

Compound-Compound Interactions

Yimusake combined with trazodone hydrochloride is highly efficacious for primary PE.

ExcerptReferenceRelevance
" This study assessed the effects of caffeine on sleep architecture and electroencephalography (EEG) spectrum alone and in combination with two different sleep-promoting medications."( Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers.
Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2009
)
0.57
" First of all, once assessed that all drugs induced dose-related antinociceptive effects, they were mixed in fixed ratio (1:1) combinations and a synergistic drug-drug interaction was obtained in all circumstances."( Fentanyl-trazodone-paracetamol triple drug combination: multimodal analgesia in a mouse model of visceral pain.
Ciruela, F; Fernández, A; Fernández-Dueñas, V; Planas, E; Poveda, R; Sánchez, S, 2011
)
0.79
"To study the clinical effects of the Chinese drug Yimusake, used alone or in combination with trazodone hydrochloride, on primary premature ejaculation (PE)."( [Yimusake alone or combined with trazodone hydrochloride for primary premature ejaculation].
Gao, G; Xu, JX; Xu, N; Yang, YY, 2012
)
0.88
"Yimusake combined with trazodone hydrochloride is highly efficacious for primary PE."( [Yimusake alone or combined with trazodone hydrochloride for primary premature ejaculation].
Gao, G; Xu, JX; Xu, N; Yang, YY, 2012
)
0.97
"5/25, 10/100, and 30/300 and investigation of potential drug-drug interaction at a dose of 10/100."( Investigations on dose proportionality and drug-drug interaction for a fixed-dose combination of trazodone and gabapentin.
Blume, HH; Calisti, F; Cattaneo, A; Comandini, A; Del Vecchio, A; Donath, F; Dragone, P; Picollo, R; Rosignoli, MT; Ruggieri, A; Todorova-Sanjari, M; Warnke, A; Wedemeyer, RS, 2021
)
0.84
"The purpose of this study was to compare the efficacy of Trazodone hydrochloride tablets alone and in combination with press-needles in the treatment of post-stroke depression."( Comparison of the efficacy of Trazodone hydrochloride tablets alone and in combination with press-needles in the treatment of post-stroke depression.
Cui, Q; Wei, W, 2023
)
1.44

Bioavailability

The bioavailability of trazodone, a new antidepressant, from 50 mg dividose (A) or film-sealed (B) tablets relative to an oral solution was determined in six healthy male subjects using 50 mg of D4-trazodone as a stable isotope labelled standard. No differences were observed in the total amount of traZodone absorbed with or without food with bioavailability values of 65 and 63 per cent, respectively.

ExcerptReferenceRelevance
" No differences were observed in the total amount of trazodone absorbed with or without food with bioavailability values of 65 +/- 6 and 63 +/- 4 per cent, respectively."( Single dose pharmacokinetics of trazodone in healthy subjects.
Dale, O; Nilsen, OG, 1992
)
0.82
"The partial area method was investigated for evaluation of equivalency in the rate of absorption of immediate release formulations."( An alternative approach for assessment of rate of absorption in bioequivalence studies.
Chen, ML, 1992
)
0.28
" Absolute bioavailability of oral trazodone averaged 70% to 90% and was unrelated to age or sex."( Trazodone kinetics: effect of age, gender, and obesity.
Blyden, GT; Burstein, ES; Friedman, H; Greenblatt, DJ; Harmatz, JS; Miller, LG; Ochs, HR; Scavone, JM; Shader, RI, 1987
)
1.99
"The bioavailability of trazodone, a new antidepressant, from 50 mg dividose (A) or film-sealed (B) tablets relative to an oral solution was determined in six healthy male subjects using 50 mg of D4-trazodone as a stable isotope labelled standard."( Comparative bioavailability of trazodone formulations using stable isotope methodology.
Gammans, RE; Mackenthun, AV; Russell, JW, 1984
)
0.86
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" However, NFZ is an inhibitor of P-gp activity at clinically relevant in vivo concentrations and may have the potential to increase bioavailability of coadministered compounds that are substrates for transport."( P-glycoprotein interactions of nefazodone and trazodone in cell culture.
Greenblatt, DJ; Perloff, MD; Störmer, E; von Moltke, LL, 2001
)
0.57
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"Relative bioavailability studies compared the pharmacokinetics of TzCOAD and trazodone immediate-release (TzIR) tablets following single- and multiple-dose administration."( Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects.
Cronjé, T; Fradette, C; Gossen, ER; Karhu, D; Mostert, A, 2011
)
0.84
"To determine the pharmacokinetics and hemodynamic effects of trazodone after IV and oral administration in dogs and bioavailability after oral administration."( Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs.
Benson, L; Jay, AR; Kravitz, A; Krotscheck, U; Mohammed, H; Mulligan, A; Parsley, E; Schwark, WS; Silva, J, 2013
)
0.87
" Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84."( Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs.
Benson, L; Jay, AR; Kravitz, A; Krotscheck, U; Mohammed, H; Mulligan, A; Parsley, E; Schwark, WS; Silva, J, 2013
)
0.63
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse."( The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants.
Eap, CB; Favre, L; Frantz, J; Garin, P; Vandenberghe, F; Vionnet, N, 2023
)
0.91

Dosage Studied

Trazodone showed linear pharmacokinetics within the dosage range investigated. In a 9 week dosing regimen, trazodone decreased microglial NLRP3 inflammasome expression and phosphorylated p38 mitogen-activated protein kinase levels.

ExcerptRelevanceReference
" The concentration pattern in blood of humans given a single dosage (50 mg) of trazodone HCl is similar to that in rabbits rather than that in rats."( Studies on metabolism of trazodone. III Species differences.
Fujita, T; Takahashi, T; Yamato, C, 1976
)
0.79
" Studies comparing multiple daytime dosing to single dosing at bedtime have shown equal efficacy in relieving depression."( Trazodone dosing regimen: experience with single daily administration.
Fabre, LF, 1990
)
1.72
" In an effort to determine whether this discrepancy may be due to possible inappropriate dosing or use of trazodone for different patient subtypes, a retrospective chart review of 138 depressed inpatients treated with amitriptyline and of 42 depressed inpatients treated with trazodone was performed to compare their respective prescribing patterns."( A drug utilization review of prescribing patterns for trazodone versus amitriptyline.
Brown, CS; Bryant, SG; Hokanson, JA, 1990
)
0.74
"), an inhibitor of trazodone metabolism, caused a greater than 30-fold leftward shift in the dose-response curve for both the reinforcement rate and the response rate."( Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine.
Hand, TH; Li, AA; Marek, GJ; Seiden, LS, 1990
)
0.89
" The authors hypothesize that fluoxetine 20 mg/day may be an ineffective dosage of the drug or that fluoxetine has a slower onset of antidepressant action than does trazodone."( A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
Cook, BL; Dunner, FJ; Garvey, MJ; Kelly, MW; Perry, PJ; Winokur, G, 1989
)
0.74
" Steady state plasma concentrations were reached by Day 2 of repeated dosing on both treatments."( Trazodone conventional and controlled-release formulations: pharmacodynamic effects after single and repeated administration.
Ankier, SI; Debbas, NM; Warrington, SJ, 1989
)
1.72
" Dothiepin and amitriptyline were both given at a dosage of 75 mg daily for the 1st week; this was then increased to 150 mg and 100 mg, respectively, for the final 5 weeks of the study."( The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline.
Blacker, R; Chapman, N; Davey, A; Shanks, NJ, 1988
)
0.49
" Using a total side effects score to assess the incidence and severity of adverse events, the two dosing regimens were found not to be significantly different."( A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice.
Davey, A, 1988
)
0.53
" While a positive correlation existed between dosage and concentration of the parent drug, no dose-response correlation could be identified within this cohort."( A retrospective evaluation of plasma trazodone concentrations and clinical response in a primary care clinic.
Garvey, MJ; Luxenberg, M; Saxena, S; Tollefson, GD, 1988
)
0.55
" Reduced clearance of trazodone among elderly men may indicate a need for dosage reduction during chronic therapy."( Trazodone kinetics: effect of age, gender, and obesity.
Blyden, GT; Burstein, ES; Friedman, H; Greenblatt, DJ; Harmatz, JS; Miller, LG; Ochs, HR; Scavone, JM; Shader, RI, 1987
)
2.03
" The target dosage was 200 mg/d."( Antidepressant therapy after stroke. A double-blind trial.
Di Ponte, P; Fortuna, IM; McDowell, FH; Orto, LA; Reding, MJ; Winter, SW, 1986
)
0.27
" In part this is due to generally exaggerated fears that primary care physicians have regarding these medications, especially the anticholinegic effects of recommended dosage levels and sudden cardiac death."( Update on some of the older and newer antidepressants.
Thompson, TL, 1985
)
0.27
"The antidepressant efficacy of trazodone has been studied during three weeks in 13 endogenously depressed patients, using a fixed dosage of 5/10 mg/kg bodyweight per day."( Trazodone in endogenous depressed patients: a negative report and a critical evaluation of the pertaining literature.
Klein, HE; Müller, N, 1985
)
2
" The mean maintenance dosage of trazodone was 300 mg (range 200-350 mg) and of imipramine 160 mg (range 150-175 mg)."( A double blind comparison of the efficacy and safety of trazodone and imipramine in endogenous depression.
Al-Yassiri, MM; Ankier, SI; Bridges, PK, 1983
)
0.8
" The results showed equivalent therapeutic efficacy for the two dosage regimens and tolerance was good in both groups."( Trazodone--a comparison of single night-time and divided daily dosage regimens.
Ankier, SI; Bouras, N; Bridges, PK; Brooks, D; Jarman, CM; Prothero, W, 1984
)
1.71
" The relative bioequivalence of the dosage formed with a power of 85% (power by conventional ANOVA was 54%)."( Comparative bioavailability of trazodone formulations using stable isotope methodology.
Gammans, RE; Mackenthun, AV; Russell, JW, 1984
)
0.55
" Therapeutic effects were the same but once daily dosage produced drowsiness whilst thrice daily dosage did not."( Trazodone in depression.
Wheatley, D, 1980
)
1.7
" Trazodone 200 mg is equal to imipramine 100 mg, and the therapeutic dosage range is 200-600 mg/d."( Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division).
Rawls, WN, 1982
)
2.62
"01), but at 150 and 180 min after dosing QS2I was significantly lower."( Hemodynamic responses of trazodone and imipramine.
Burgess, CD; George, CF; Hames, TK, 1982
)
0.57
" The results indicate that neither the route of administration nor the dosage schedule affects in significant manner the pharmacokinetics of trazodone, but the pharmacokinetic parameters depend upon the dose used."( Pharmacokinetics of trazodone after different routes of administration.
Danek, L; Melzacka, M; Rurak, A, 1981
)
0.79
" Dosing ranged from 225 to 450 mg/day for bupropion and 150 to 400 mg/day for trazodone."( Comparison of bupropion and trazodone for the treatment of major depression.
Billow, AA; Branconnier, RJ; Johnston, JA; Lineberry, CG; Samara, B; Weisler, RH, 1994
)
0.81
" Trazodone showed linear pharmacokinetics within the dosage range investigated."( Pharmacokinetics of trazodone during multiple dosing to psychiatric patients.
Dale, O; Husebø, B; Nilsen, OG,
)
1.37
" The aim of the present study was to examine whether pindolol may increase the efficacy of a subtherapeutical dosage of trazodone in the treatment of major depression and TRD, defined according to the Thase and Rush criteria (1995)."( Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
Desnyder, R; Maes, M; Vandoolaeghe, E, 1996
)
0.8
" For both trazodone and mCPP, significant linear relationships were found between plasma concentration after initial dosing and the average of 3 weeks' plasma concentrations."( Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone.
Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Tokinaga, N; Yasui, N, 1997
)
1
" In these rats, the power values were less than three times those before the dosing of PTZ or beta-CCM."( [A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power-spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists].
Hatsuda, S; Matsubara, M; Miura, K; Murakami, H; Nakazawa, K; Ohara, M; Sugita, S; Suzuki, S; Terashima, M, 1997
)
0.3
" As a result, trazodone at the dosage of 50-100 mg/day improved sleep disorders, particularly at the 100 mg/day dosage."( Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: dose-finding study with no concomitant use of hypnotic agent.
Horikoshi, R; Kaneko, Y; Kumashiro, H; Mashiko, H; Niwa, S; Numata, Y; Suzuki, S; Watanabe, Y, 1999
)
1.07
" Surprisingly, no significant changes in striatal 5-HT or its metabolite were observed following the same dosage and time course."( Pharmacokinetic and pharmacodynamic analyses of trazodone in rat striatum by in vivo microdialysis.
Chen, CF; Cheng, FC; Kuo, JS; Tsai, TH; Wu, YS, 1999
)
0.56
" Concentrations of NFZ and TZD achieved in the intestine after chronic oral dosing may induce P-gp expression and reduce absorption of coadministered drugs."( P-glycoprotein interactions of nefazodone and trazodone in cell culture.
Greenblatt, DJ; Perloff, MD; Störmer, E; von Moltke, LL, 2001
)
0.57
" The total daily dosage of trazodone was 100 mg (50 mg in one subject), and of imipramine 40 mg (20 mg in one subject)."( Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature.
Endo, S; Nakamura, S; Suzuki, H; Yamadera, H, 2002
)
1
" The most commonly administered drug was trazodone at a mean dosage of 70 mg/day (range 50-100 mg/day)."( Pharmacologic management by clinical pharmacists of behavioral and psychological symptoms of dementia in nursing home residents: results from a pilot study.
Allie, ND; Eng, M; Rojas-Fernandez, CH, 2003
)
0.58
" The proposed techniques were successfully applied to the determination of PR in tablet dosage forms and human serum."( Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum.
Ozkan, SA; Uslu, B, 2003
)
0.32
" The suggested procedures could be used for the determination of trazodone, famotidine, and diltiazem, both in pure and dosage forms without interference from common excipients."( New colorimetric methods for the determination of trazodone HCl, famotidine, and diltiazem HCl in their pharmaceutical dosage forms.
Abdellatef, HE; Ayad, MM; Hosny, MM; Shalaby, A, 2003
)
0.81
" Nine female patients with a score of at least "mild akathisia" on the Barnes Akathisia Scale, and receiving a stable dose of antipsychotic medication, were administered trazodone, titrated up to a dosage of 100 mg/day over a period of 5 days."( Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone.
Bar, F; Kotler, M; Poyurovsky, M; Strous, RD; Stryjer, R; Weizman, A,
)
0.56
" The heterocyclic agent trazodone significantly inhibited paw oedema by 46 and 41% at 1 and 2h after dosing at the highest dose (40 mg kg(-1)) examined."( Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.
Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003
)
0.63
" Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging."( The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.
Buysse, DJ; Cassella, J; Mendelson, WB; Meyer, RE; Roehrs, T; Roth, T; Walsh, JK; Woods, JH, 2004
)
0.32
" There are virtually no dose-response data for trazodone vis-à-vis sleep and, similarly, no available data on tolerance to its possible hypnotic effects."( The use of trazodone as a hypnotic: a critical review.
James, SP; Mendelson, WB, 2004
)
0.97
" The study is designated as semi-naturalistic due to the fact that, although the venlafaxine treatment regimen was strictly defined, the timing of the trazodone introduction and the dosage were determined by the clinicians."( Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study.
Aït-Ameur, A; Bertschy, G; Ferrero, F; Muscionico, M; Osiek, C; Ragama-Pardos, E; Roth, L, 2005
)
1.97
" AMI-193, a 5-HT(2A) antagonist (10(-10) to 10(-5) M), reduced GABA release in a dose-response manner, while it induced an increase of 5-HT outflow."( A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone.
Garrone, B; Luparini, MR; Pazzagli, M; Pepeu, G; Pinza, M, 2004
)
0.55
" The assay was applied to a pharmacokinetic study in mice to determine dosing schedules that would approximate therapeutic ZD6474 levels determined in humans."( Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Bradshaw, EL; Gustafson, DL; Long, ME; Zirrolli, JA, 2005
)
0.33
"A simple and rapid extraction spectrophotometric procedure has been developed for the determination of tricyclic anti-depressant drugs such as trazodone (TZH), amineptine (APH) and amitriptyline (ATPH) hydrochlorides in pure form and in different dosage forms."( Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation using methyl orange and bromocresol green reagents.
Mohamed, GG; Mohamed, NA; Nour El-Dien, FA, 2006
)
0.81
"Extraction spectrophotometric method has been developed for the determination of tricyclic drugs such as trazodone (TZH), amineptine (APH) and amitriptyline (ATPH) hydrochlorides in pure form and in the dosage forms coming from different Egyptian markets."( Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation with molybdenum and thiocyanate.
Khalil, SM; Mohamed, GG; Mohamed, NA; Nour El-Dien, FA, 2006
)
0.82
" The injury appears as glandular swellings and/or decreased salivation with 131I dosage and passage of time playing significant roles."( False-positive xerostomia following radioactive iodine treatment: case report.
Mandel, L; Mandel, SJ, 2007
)
0.34
" The method is applicable for the assay of the investigated drugs in different dosage forms and the results are in good agreement with those obtained by the official method."( Utility of 7,7,8,8-tetracyanoquinodimethane charge transfer reagent for the spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides.
El-Dien, FA; Mohamed, GG; Mohamed, NA, 2007
)
0.55
"A transdermal dosage form of trazodone hydrochloride (TZN) may be useful in the treatment of moderate to severe depression in schizophrenic patients by providing prolonged duration of action."( Effect of penetration enhancers on skin permeation of trazodone hydrochloride from matrix type transdermal formulation through mouse and human cadaver epidermis.
Bhattacharya, A; Das, MK; Ghosal, SK,
)
0.67
" Following recovery, animals were dosed with caffeine (10 mg/kg) alone or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg)."( Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption.
Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2009
)
0.56
" Greater clinical severity and low initial dosing may increase the risk of switching antidepressants."( Antidepressant switching among adherent patients treated for depression.
Hassan, M; Marcus, SC; Olfson, M, 2009
)
0.35
" Interestingly, drug dosage reduction permitted to reduce the incidence of possible adverse effects, namely exploratory activity and motor coordination, thus it was demonstrated that it improved the benefit/risk profile of such treatment."( Fentanyl-trazodone-paracetamol triple drug combination: multimodal analgesia in a mouse model of visceral pain.
Ciruela, F; Fernández, A; Fernández-Dueñas, V; Planas, E; Poveda, R; Sánchez, S, 2011
)
0.79
" Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period."( Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study.
Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011
)
2.72
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" At each daily visit, signs and symptoms were assessed, and medications and dosing instructions were given for the following 24 hours."( A nonopioid procedure for outpatient opioid detoxification.
Baier, AR; Coons, EE; Fingesten, A; Ockert, DM; Volpicelli, JR, 2011
)
0.37
" Optimal follow-up visits and adequate antidepressant dosing was associated with better adherence during both treatment phases, as was use of other psychotropic medications."( Factors associated with antidepressant adherence for Medicaid-enrolled children and adolescents.
Bridge, JA; Campo, JV; Fontanella, CA; Marcus, SC, 2011
)
0.37
" Trazodon CR is an orally administered controlled release form, which simplifies its dosage and reduces the risk of adverse effects."( [Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression].
Dudek, D; Heitzman, J; Jarema, M; Landowski, J; Rabe-Jabłońska, J; Rybakowski, J,
)
0.13
" Individualized approaches in dosing intervals may be necessary for dogs receiving oral trazodone."( Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs.
Benson, L; Jay, AR; Kravitz, A; Krotscheck, U; Mohammed, H; Mulligan, A; Parsley, E; Schwark, WS; Silva, J, 2013
)
0.85
" After 3 days, administration of tramadol was discontinued, and the trazodone dosage was increased (approx 7 mg/kg [3."( Use of trazodone to facilitate postsurgical confinement in dogs.
Griffith, E; Gruen, ME; Hamilton, A; Roe, SC; Sherman, BL, 2014
)
1.09
" It is a major determinant of half-life and dosing frequency of a drug."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" Patients received trazodone or mirtazapine for at least three months at the dosage that was effective in the titration period."( Subjective hypnotic efficacy of Trazodone and Mirtazapine in patients with chronic insomnia: a retrospective, comparative study.
Cardinali, V; Carnicelli, M; Federico, F; Mogavero, MP; Savarese, M,
)
0.74
"This review describes trazodone mechanism of action, formulation, dosage and adverse effects and then summarizes the beneficial effects of trazodone in the treatment of various psychiatric and medical conditions such as major depression, as well non-approved FDA indications such as insomnia,anxiety disorders, posttraumatic stress disorder, obsessive compulsive disorder, feeding and eating disorders, substance use disorders, behavioral disturbances associated with cognitive dysfunction, sexual dysfunction, certain pain conditions, and rehabilitation after acute ischemic stroke."( A review of trazodone use in psychiatric and medical conditions.
Khouzam, HR, 2017
)
1.15
" Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract."( Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.
Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019
)
0.73
" Multiple dosage of TSR and TIR reached steady state after 7 days, with no accumulation phenomenon observed."( Pharmacokinetics of trazodone sustained-release tablets in healthy subjects: Three open-label, randomized crossover studies
.
Gong, Y; Luo, WW; Peng, WX; Zhang, QZ; Zhu, JL; Zhu, RH, 2019
)
0.84
" Parallel rightward shift of dose-response curves for trazodone recorded in higher phenylephrine concentrations (10-100 μM) indicated competitive antagonism at α1-adrenoceptors."( Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and α1-adrenoceptor antagonism.
Bonfiglio, F; Corradetti, R; Magnani, M; Mlinar, B; Montalbano, A; Polenzani, L, 2019
)
1.06
" This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling."( Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction.
Calisti, F; Chetty, M; Garofolo, F; Ke, AB; Oggianu, L; Petrucci, V; Picollo, R; Tongiani, S, 2020
)
1.09
" Zolpidem has been marketed in new dosage forms that include sublingual tablets and oral spray formulations."( New pharmacologic agents for insomnia and hypersomnia.
Earl, DC; Van Tyle, KM, 2020
)
0.56
"Recent advancements in the treatment of insomnia includes agents with novel mechanisms, new indications, and new dosage forms."( New pharmacologic agents for insomnia and hypersomnia.
Earl, DC; Van Tyle, KM, 2020
)
0.56
" A previously verified physiologically-based pharmacokinetic model based on in vitro and in vivo information on trazodone pharmacokinetics was applied, aiming at predicting brain receptor occupancy (RO) after single and repeated dosing of the IR formulation and repeated dosing of the OAD formulation in healthy subjects."( Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations.
Comandini, A; Di Dato, G; Jones, HM; Ke, AB; Mangano, G; McFeely, S; Oggianu, L; Rosignoli, MT, 2022
)
1.2
" After experiencing a major Covid-19-related personal trauma, patients showed clinical worsening which required dosage adjustment (20 mg/day vortioxetine; 600 mg/day trazodone, and 200 mg/day sertraline) and, for some of them, hospitalisation."( Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma.
Amici, E; De Filippis, S; Di Giovanni, A; Giovanetti, V; Kotzalidis, GD; Lombardozzi, G; Matrone, M; Perrini, F; Trovini, G, 2022
)
0.92
" In a 9 week dosing regimen, trazodone decreased microglial NLRP3 inflammasome expression and phosphorylated p38 mitogen-activated protein kinase levels, which correlated with the NLRP3 inflammasome, the UPR effector ATF4, and total tau levels."( Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice.
Cella, C; de Oliveira, P; Dijk, DJ; Gilmour, G; Locker, N; Mendis, A; Ravindran, KKG; Wafford, K; Winsky-Sommerer, R, 2022
)
1.21
" A dose-response relationship was identified for level of care and medical outcome."( Single-substance trazodone exposures reported to US poison centers from 2000 to 2019.
Husak, N; Klein-Schwartz, W; Leonard, JB; Seung, H, 2022
)
1.06
"42) taking trazodone (median dosage 50 mg/d, range 25-200 mg) for insomnia and 19 children (11 girls and 8 boys, mean age 13."( Trazodone affects periodic leg movements and chin muscle tone during sleep less than selective serotonin reuptake inhibitor antidepressants in children.
Bruni, O; DelRosso, LM; Ferri, R; Fickenscher, A; Mogavero, MP; Schenck, CH, 2022
)
2.55
"Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant."( Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis.
Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023
)
1.12
" Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone."( Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Keidan, L; Pick, CG; Schreiber, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
adrenergic antagonistAn agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists.
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonin uptake inhibitorA compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
N-alkylpiperazine
N-arylpiperazine
triazolopyridine
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency26.36480.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency26.36480.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency24.70280.100020.879379.4328AID588453; AID588456
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID504865
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.84890.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency33.58750.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency12.58930.00207.533739.8107AID891
D(1A) dopamine receptorHomo sapiens (human)Potency6.42800.02245.944922.3872AID488982; AID488983
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.58930.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency11.22020.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency22.38720.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.09100.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.04700.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)119.33330.11007.190310.0000AID1443980; AID1443986; AID1473738
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.11800.00010.532610.0000AID1907051
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.90900.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.34100.00010.807410.0000AID625201
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)4.48500.00000.74728.0000AID1659258
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.01700.00040.908610.0000AID5482
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.28100.00021.874210.0000AID36846
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.38900.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.17800.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)1.94200.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.28200.00030.483410.0000AID625203
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.31100.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.20090.00010.739610.0000AID4411; AID625190
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.28100.00021.270410.0000AID36846
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.26500.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.13000.00000.360910.0000AID625200
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.13150.00010.88018.8500AID1659260; AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.00560.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.09100.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.04700.00010.954910.0000AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.31100.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.17800.00031.29679.2440AID625190
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.19200.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.10200.00000.70488.1930AID625222
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.36100.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.04200.00000.511010.0000AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)3.74300.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki1.27100.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.10700.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.06800.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.28100.00001.819410.0000AID36846
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)2.20300.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.92600.00000.490110.0000AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminRattus norvegicus (Norway rat)Kd7.95001.47006.53179.3100AID1215123
5-hydroxytryptamine receptor 1AHomo sapiens (human)EC50 (µMol)0.78500.00010.25718.0000AID1659259
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (287)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (65)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (203)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1659258Antagonist activity at D2 receptor (unknown origin) by HTRF cAMP assay2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID204282Inhibition of [3H](+)-pentazocine binding to Sigma opioid receptor type 1 of pig brain membranes at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID6421Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID1636377Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 8.7 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1215123Binding affinity to Wistar rat serum albumin2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1215122Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1659260Antagonist activity at 5HT2A receptor (unknown origin) by HTRF cAMP assay2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID298032Acid dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID36846Compound was tested for the inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID145555Inhibition of [3H]desmethylimipramine binding to Norepinephrine receptor of rat cortical membrane at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36712Binding affinity by its ability to displace [3H]prazosin radioligand from Alpha-1 adrenergic receptor on rat cerebral cortex2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
alpha(1)-Adrenoceptor antagonists. Rational design, synthesis and biological evaluation of new trazodone-like compounds.
AID37025Displacement of [3H]prazosin from Alpha-1 adrenergic receptor of rat cortical membrane at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID5482Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64755Displacement of [3H]sulpiride from rat striatal membrane Dopamine receptor D2 at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID4411Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID298031Lipophilicity, log D at pH7.42007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID5493Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1659261Agonist activity at D2 receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID1283242Decrease in lanosterol levels in mouse Neuro2a cells by LC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID705591Lipophilicity, log D of the compound2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1215121Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1283241Decrease in desmosterol levels in mouse Neuro2a cells by LC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1215120Binding affinity to Wistar rat brain lipid by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID88623Inhibition of [3H]pyrilamine binding to Histamine H1 receptor of bovine cerebellar membrane at 10e-7 M1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity.
AID1907051Displacement of 8-OH-DPAT from human 5-HT1AR in human brain frontal cortex incubated for 30 mins by liquid scintillation counter analysis
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1215124Binding affinity to Wistar rat brain lipid assessed as percentage unbound by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1659259Agonist activity at 5HT1A receptor (unknown origin) by calcium-dye based FLIPR assay2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID1768730Relative lipophilicity of the compound in methanol assessed as retardation factor by reversed-phase TLC analysis2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID1636434Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 12.9 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID680920TP_TRANSPORTER: Western blot, LS180V cell2001Journal of clinical pharmacology, Jul, Volume: 41, Issue:7
P-glycoprotein interactions of nefazodone and trazodone in cell culture.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID112173Effective dose was evaluated for its antagonism to reserpine induced hypothermia in mice by intraperitoneal administration1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID1659262Agonist activity at D2 receptor (unknown origin) relative to 10 uM dopamine2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1215126Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1232316Volume of distribution at steady state in mouse2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1768729Lipophilicity, logP of compound by shake flask method2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID1346868Rat 5-HT2C receptor (5-Hydroxytryptamine receptors)1996Psychopharmacology, Aug, Volume: 126, Issue:3
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.
AID1346868Rat 5-HT2C receptor (5-Hydroxytryptamine receptors)2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID624222Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID624223Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)1996Psychopharmacology, Aug, Volume: 126, Issue:3
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.
AID624222Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A1996Psychopharmacology, Aug, Volume: 126, Issue:3
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,304)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990478 (36.66)18.7374
1990's253 (19.40)18.2507
2000's239 (18.33)29.6817
2010's221 (16.95)24.3611
2020's113 (8.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 133.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index133.82 (24.57)
Research Supply Index7.47 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index262.45 (26.88)
Search Engine Supply Index2.08 (0.95)

This Compound (133.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials295 (20.12%)5.53%
Reviews170 (11.60%)6.00%
Case Studies327 (22.31%)4.05%
Observational8 (0.55%)0.25%
Other666 (45.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (55)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study [NCT01142258]Phase 340 participants (Actual)Interventional2010-03-31Completed
Efficacy and Safety of Fixed-Dose Combination (FDC) Products Containing Trazodone and Gabapentin in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose Finding Study. [NCT03749642]Phase 2240 participants (Actual)Interventional2018-11-22Completed
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium: A Four-arm Prospective, Randomized, Double-blind, Placebo-controlled Pilot Study [NCT02118688]Phase 40 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to Lack of enrollment)
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder. [NCT00775203]Phase 3412 participants (Actual)Interventional2007-06-30Completed
A Randomized, Double-Blind, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly-dosed Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New S [NCT03852160]Phase 30 participants (Actual)Interventional2019-12-01Withdrawn(stopped due to New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study)
Stabilisation de la qualité du Sommeil Chez le Sujet en Douleurs Orofaciales Chroniques - étude expérimentale en chassé croisé : Trazodone/ Placebo [NCT03522207]Phase 43 participants (Actual)Interventional2018-10-15Terminated(stopped due to shortstaff at sleep lab)
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]1,600 participants (Anticipated)Observational2018-10-04Recruiting
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial [NCT04302870]Phase 2/Phase 3800 participants (Anticipated)Interventional2020-02-27Recruiting
A Randomized, Double-blind Study Comparing the Efficacy and Safety of Trazodone OAD and Venlafaxine XR in the Treatment of Patients With Major Depressive Disorder. [NCT02086929]Phase 3364 participants (Actual)Interventional2012-12-31Completed
Single Centre, Single Dose, Randomised, Negative and Positive-controlled, Double-blind Trazodone vs. Negative Control (Placebo), Open-label vs. Positive Control (Moxifloxacin), 5-way Cross-over QT/QTc Study [NCT03516630]Phase 120 participants (Actual)Interventional2017-03-20Completed
Pharmacokinetics Study of Trazodone Hydrochloride Prolonged-Released Tablets in Chinese Healthy Volunteers [NCT02785614]Phase 112 participants (Actual)Interventional2017-05-01Completed
Comparative Effectiveness of Zolpidem/Trazodone and Cognitive Behavioral Therapy for Insomnia in Rural Adults [NCT04468776]Phase 41,200 participants (Anticipated)Interventional2022-02-25Active, not recruiting
The Efficacy of Trazodone for Selective Serotonin Reuptake Inhibitor-induced Sexual Dysfunction [NCT01097980]56 participants (Actual)Interventional2010-04-30Completed
The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression [NCT04162743]Phase 422 participants (Actual)Interventional2019-02-01Completed
[NCT00659919]Phase 413 participants (Actual)Interventional2000-11-30Completed
Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic [NCT02699138]Early Phase 10 participants (Actual)Interventional2021-10-31Withdrawn(stopped due to Research fellow left institution)
Pharmacokinetics Study of Trazodone Hydrochloride Prolonged -Released Tablets in Chinese Healthy Volunteers [NCT02785601]Phase 115 participants (Actual)Interventional2017-05-01Completed
A Randomized, Four-way Crossover Pilot Study to Compare the Relative Bioavailability of Two Prototype Once-a-day Trazodone Hydrochloride Products and Two Marketed Reference Products Following an Equivalent Daily Dose Administration Under Fasting Condition [NCT01121913]Phase 124 participants (Actual)Interventional2005-03-31Completed
Crossover Comparative Bioavailability Study of Trazodone Contramid(r) OAD 300 mg Extended-release Caplets and Desyrel(r) 100 mg Immediate-release Tablets in Healthy Adult Volunteers Under Fasting Conditions [NCT00839072]Phase 124 participants (Actual)Interventional2009-02-28Completed
Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II) [NCT00791739]Phase 466 participants (Actual)Interventional2008-04-30Completed
Investigating the Effectiveness of Electronically Delivered Cognitive Behavioural Therapy (e-CBTi) Compared to Pharmaceutical Interventions in the Treatment of Insomnia [NCT05125146]60 participants (Anticipated)Interventional2021-11-01Recruiting
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]1,000 participants (Anticipated)Interventional2006-04-30Recruiting
Examination of the Pharmacokinetic Properties of Three Generic Medications and Their Respective Brand Preparations in Healthy Male Volunteers [NCT01400165]Phase 130 participants (Anticipated)Interventional2011-07-31Recruiting
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone (REST) [NCT05282550]Phase 2100 participants (Anticipated)Interventional2023-01-04Recruiting
Randomized Controlled Trial of Trazodone Dose Tolerance and APAP Adherence [NCT02945644]Phase 145 participants (Anticipated)Interventional2017-02-13Suspended(stopped due to COVID19 pandemic)
Treating Residual OSA With Endotype-directed Pharmacotherapy (Aim 3) [NCT05293600]Phase 1/Phase 270 participants (Anticipated)Interventional2022-09-01Not yet recruiting
A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered Once Daily) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Th [NCT01121926]Phase 130 participants (Actual)Interventional2008-01-31Completed
Efficacy of Trazodone vs. Cognitive Behavioral Therapy in Patients With Chronic Insomnia Associated With Objective Short Sleep Duration [NCT01348542]24 participants (Actual)Interventional2011-04-30Completed
A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered as a Single Dose) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administe [NCT01121900]Phase 126 participants (Actual)Interventional2008-06-30Completed
A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder [NCT01857596]Phase 1/Phase 230 participants (Actual)Interventional2013-04-30Completed
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD) [NCT03534284]Phase 3126 participants (Actual)Interventional2018-09-19Completed
A Clinical Study on Efficacy And Safety of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression A Multicenter, Randomized, Double-Blind, Parallel Controlled Study [NCT01524497]Phase 2/Phase 3382 participants (Actual)Interventional2011-11-30Completed
Randomized-Controlled Trial of Trazodone on Reducing Plasma sST2 Level and Neurodegeneration Progression in Patients With Amnestic Mild Cognitive Impairment and Obstructive Sleep Apnea [NCT05209035]Phase 4124 participants (Anticipated)Interventional2022-05-10Recruiting
Sentra PM (a Medical Food) and Trazadone in the Management of Sleep Disorders [NCT01468038]Phase 3111 participants (Actual)Interventional2008-04-30Completed
Long-term Treatment With Trazodone Once-a-Day (TzOAD) in Patients With MDD: an Observational, Prospective Study [NCT04295941]200 participants (Actual)Observational2020-06-23Completed
[NCT00000179]Phase 30 participants InterventionalCompleted
Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder. [NCT04082806]Phase 254 participants (Actual)Interventional2020-08-06Completed
Trazodone for Sleep Disturbance - Early Alcohol Recovery [NCT00027053]Phase 2173 participants (Actual)Interventional2002-06-30Completed
Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury [NCT02922894]Phase 4100 participants (Anticipated)Interventional2017-06-09Recruiting
[NCT02655354]635 participants (Actual)Interventional2015-10-31Completed
A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis [NCT01943435]259 participants (Actual)Interventional2013-11-20Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]Phase 41,080 participants (Anticipated)Interventional2012-06-30Recruiting
Sequenced Therapies for Comorbid and Primary Insomnias [NCT01651442]211 participants (Actual)Interventional2012-08-01Completed
Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study [NCT05307003]60 participants (Anticipated)Observational2023-04-01Recruiting
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans: an Open (e.g. Unblinded) Randomized Stay-Switch Pilot Trial [NCT01662297]Phase 41 participants (Actual)Interventional2012-07-31Terminated(stopped due to it became clear that recruitment was infeasible)
The Effects of Trazodone on the Severity of Obstructive Sleep Apnea [NCT01817907]15 participants (Actual)Interventional2013-03-31Completed
Insomnia and Drug Relapse Risk [NCT00253890]Phase 3137 participants (Actual)Interventional2005-10-31Completed
CSP #2016 - National Adaptive Trial for PTSD Related Insomnia [NCT03668041]Phase 31,224 participants (Anticipated)Interventional2021-02-25Recruiting
Pathogenesis of Sleep Disordered Breathing in Spinal Cord Injury Patients [NCT02458469]Phase 215 participants (Actual)Interventional2015-05-14Completed
Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Pilot Study. [NCT03202979]Phase 2142 participants (Actual)Interventional2017-05-16Completed
A Randomized, Two-way Cross-over Comparative Bioavailability Study of 300 mg Trazodone Hydrochloride Containing New Polymer vs. 300 mg Trazodone Hydrochloride Containing Contramid® Prolonged-release Tablets Under Fasting Conditions [NCT05136521]Phase 128 participants (Actual)Interventional2020-02-17Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study) [NCT05085808]Phase 430 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone [NCT05299398]Phase 128 participants (Anticipated)Interventional2022-09-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00253890 (1) [back to overview]Sleep Quality, as Measured by Total Sleep Time
NCT00775203 (14) [back to overview]Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit
NCT00775203 (14) [back to overview]Discontinuation Due to Lack of Efficacy
NCT00775203 (14) [back to overview]Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit
NCT00775203 (14) [back to overview]Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit
NCT00775203 (14) [back to overview]Awakening During the Night at Each Visit
NCT00775203 (14) [back to overview]Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit
NCT00775203 (14) [back to overview]Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit
NCT00775203 (14) [back to overview]Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline
NCT00775203 (14) [back to overview]Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline
NCT00775203 (14) [back to overview]HAMD-17 Remitters at Each Visit
NCT00775203 (14) [back to overview]HAMD-17 Responders at Each Visit
NCT00775203 (14) [back to overview]Overall Quality of Sleep at Each Visit
NCT00775203 (14) [back to overview]Trouble Falling Asleep at Each Visit
NCT00775203 (14) [back to overview]Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit
NCT00839072 (6) [back to overview]Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]
NCT00839072 (6) [back to overview]Bioequivalence Based on AUC∞
NCT00839072 (6) [back to overview]Bioequivalence Based on AUCT
NCT00839072 (6) [back to overview]Bioequivalence Based on Cmax
NCT00839072 (6) [back to overview]Time of Maximum Measured Plasma Concentration (Tmax)
NCT00839072 (6) [back to overview]Apparent Terminal Elimination Half-Life [T½el]
NCT01121900 (7) [back to overview]Apparent Terminal Elimination Rate Constant (λz)
NCT01121900 (7) [back to overview]Apparent Terminal Half-life (t½.z)
NCT01121900 (7) [back to overview]Area Under the Plasma Concentration vs. Time Data Pairs, for the First 24 Hours [AUC(0-24)]
NCT01121900 (7) [back to overview]Bioequivalence Based Cmax
NCT01121900 (7) [back to overview]Bioequivalence Based on AUC(0-∞)
NCT01121900 (7) [back to overview]Bioequivalence Based on AUC(0-tlast)
NCT01121900 (7) [back to overview]Time to Maximum Plasma Concentration (Tmax)
NCT01121913 (6) [back to overview]Apparent First Order Terminal Rate Constant [λz]
NCT01121913 (6) [back to overview]Apparent Terminal Half-life (t½.z)
NCT01121913 (6) [back to overview]Bioequivalence Based on AUC(0-∞)
NCT01121913 (6) [back to overview]Bioequivalence Based on AUC(0-t)
NCT01121913 (6) [back to overview]Bioequivalence Based on Cmax
NCT01121913 (6) [back to overview]Time to the Maximum Concentration (Tmax)
NCT01121926 (7) [back to overview]Bioequivalence Based on AUCss
NCT01121926 (7) [back to overview]Bioequivalence Based on Cmax,ss
NCT01121926 (7) [back to overview]Minimum Plasma Concentration (Cmin,ss)
NCT01121926 (7) [back to overview]Percentage Peak-Trough Fluctuation (%PTF)
NCT01121926 (7) [back to overview]Percentage Swing
NCT01121926 (7) [back to overview]Plasma Concentration at 24 Hours Post-evening Dose (C24h)
NCT01121926 (7) [back to overview]Time to Peak Exposure (Tmax)
NCT01348542 (6) [back to overview]Change in Objective Actigraphy Sleep Duration From Baseline to Follow up (9 Months)
NCT01348542 (6) [back to overview]Change in Objective Actigraphy Sleep Duration From Baseline to Post Treatment (3 Months)
NCT01348542 (6) [back to overview]Change in Objective Polysomnography Sleep Duration From Baseline to Follow up (9 Months)
NCT01348542 (6) [back to overview]Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months)
NCT01348542 (6) [back to overview]Change From Baseline in Subjective Severity of Sleep Disturbance at 3 Months
NCT01348542 (6) [back to overview]Change From Baseline in Subjective Severity of Sleep Disturbance at 9 Months
NCT01651442 (1) [back to overview]Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index
NCT01662297 (9) [back to overview]Change in Insomnia Severity Index (ISI) Scores
NCT01662297 (9) [back to overview]Change in Alcohol Urge Questionnaire (AUQ)Scores Over Time
NCT01662297 (9) [back to overview]Change in Average Pittsburgh Sleep Quality Inventory (PSQI)Score
NCT01662297 (9) [back to overview]Change in Brief Symptom Inventory (BSI) Over Time
NCT01662297 (9) [back to overview]Change in Epworth Sleepiness Scale (ESS) Over Time
NCT01662297 (9) [back to overview]Change in RAND Short Form 36 Item Health Survey (RAND-SF36) General Health Subscale Over Time
NCT01662297 (9) [back to overview]Medical Outcomes Study Sleep Scale- Sleep Index (Short)
NCT01662297 (9) [back to overview]Percentage of Heavy Drinking Days
NCT01662297 (9) [back to overview]Percentage of Negative Urine Drug Screens
NCT01817907 (2) [back to overview]Apnea-Hypopnea Index
NCT01817907 (2) [back to overview]Arousal Threshold (cmH2O)
NCT01943435 (3) [back to overview]Self Paced Walking Test (SPWT)
NCT01943435 (3) [back to overview]Sense Wear Armband
NCT01943435 (3) [back to overview]Swiss Spinal Stenosis (SSS) Questionnaire Score
NCT02458469 (2) [back to overview]CO2 Reserve (Delta-PETCO2-AT)
NCT02458469 (2) [back to overview]Apnea-Hypopnea Index (AHI)
NCT02655354 (13) [back to overview]Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Cognitive Impairment Scale
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]SF-36 Quality of Life
NCT02655354 (13) [back to overview]TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]Brief Pain Inventory
NCT02655354 (13) [back to overview]TSOS Patient Satisfaction: Overall Health Care

Sleep Quality, as Measured by Total Sleep Time

Number of minutes spent sleeping during sleep period, as measured by daily sleep diary. (NCT00253890)
Timeframe: Baseline to 1-month

Interventionminutes (Mean)
Trazodone339
Placebo329

[back to top]

Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit

"The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: Compared to his condition at the start of the study, how much has this patient changed? which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse." (NCT00775203)
Timeframe: Week 8

InterventionUnits on the CGI-I scale (Mean)
Trazodone Contramid OAD2.4
Placebo2.5

[back to top]

Discontinuation Due to Lack of Efficacy

Number of patients who discontinued due to lack of efficacy during the whole study period (8 weeks). (NCT00775203)
Timeframe: Baseline to Week 8

Interventionparticipants (Number)
Trazodone Contramid OAD8
Placebo9

[back to top]

Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit

"Patients were responders if the PGI-I rating was Much Improved or Very Much Improved. The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: Since the start of the study, my overall status with regard to depression is? which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients." (NCT00775203)
Timeframe: Week 8

Interventionparticipants (Number)
Trazodone Contramid OAD90
Placebo80

[back to top]

Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit

"The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: Since the start of the study, my overall status with regard to depression is? which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse." (NCT00775203)
Timeframe: Week 8

InterventionUnits on PGI-I scale (Mean)
Trazodone Contramid OAD2.6
Placebo2.8

[back to top]

Awakening During the Night at Each Visit

"Awakening during the night was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: Since the last study visit did you awaken during the night?." (NCT00775203)
Timeframe: Weeks 1, 2, 3, 4, 6, 8

,
InterventionUnits on a scale (Mean)
Score at Baseline (n=202, n=204)Score at Week 1 (n=196, n=199)Score at Week 2 (n=200, n=203)Score at Week 3 (n=201, n=204)Score at Week 4 (n=201, n=204)Score at Week 6 (n=201, n=204)Score at Week 8 (n=201, n=204)
Placebo3.22.72.52.62.62.52.5
Trazodone Contramid OAD3.22.42.42.22.22.22.2

[back to top]

Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit

"The CGI-Severity (CGI-S) consists of one question for the investigator: Considering your total clinical experience with this particular population, how mentally ill is the patient at this time? which is rated on the following seven-point scale: 1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients." (NCT00775203)
Timeframe: Baseline to Weeks 1, 2, 3, 4, 6, 8

,
InterventionUnits on CGI-S scale (Mean)
Change in CGI-S score at Week 1 (n=197, n=199)Change in CGI-S score at Week 2 (n=201, n=203)Change in CGI-S score at Week 3 (n=202, n=204)Change in CGI-S score at Week 4 (n=202, n=204)Change in CGI-S score at Week 6 (n=202, n=204)Change in CGI-S score at Week 8 (n=202, n=204)
Placebo-0.5-0.8-1.1-1.3-1.4-1.4
Trazodone Contramid OAD-0.6-1.0-1.4-1.6-1.7-1.7

[back to top]

Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit

Change from baseline in the HAMD-17, item 1: Depressed Mood item, at each post-baseline visit. The Depressed Mood item is rated on a 5-point scale ranging from rating of 0=absent; to 4=very severe. (NCT00775203)
Timeframe: Baseline to Weeks 1, 2, 3, 4, 6, 8

,
InterventionPoints on the HAMD scale (Mean)
Change in score at Week 1 (n=197, n=199)Change in score at Week 2 (n=201, n=203)Change in score at Week 3 (n=202, n=204)Change in score at Week 4 (n=202, n=204)Change in score at Week 6 (n=202, n=204)Change in score at Week 8 (n=202, n=204)
Placebo-0.5-0.8-1.0-1.2-1.3-1.3
Trazodone Contramid OAD-0.7-1.1-1.4-1.5-1.5-1.6

[back to top]

Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline

The Hamilton Depression Rating Scale 17 items [HAMD-17] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill). (NCT00775203)
Timeframe: Baseline to Week 8

,
InterventionPoints on HAMD-17 scale (Mean)
BaselineWeek 8 or LOCFChange from baseline
Placebo22.413.2-9.3
Trazodone Contramid OAD23.211.8-11.4

[back to top]

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10 item clinician-administered depression rating scale. The 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) are rated on a scale ranging from 0 (low severity/difficulty) to 6 (high severity/difficulty) with anchors at 2-point intervals. The overall total score range is from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00775203)
Timeframe: Baseline to Week 8

,
InterventionUnits on MADRS scale (Mean)
Baseline (n=202, n=204)Week 8 (n=178, n=182)Change from baseline (n=178, n=182)
Placebo31.917.7-14.1
Trazodone Contramid OAD32.616.0-16.6

[back to top]

HAMD-17 Remitters at Each Visit

Number of patients who are remitters (defined as patients who achieved a HAMD-17 total score ≤7) at each post-baseline visit. (NCT00775203)
Timeframe: Weeks 1, 2, 3, 4, 6, 8

,
InterventionParticipants (Number)
Number of remitters at Week 1 (n=197, n=199)Number of remitters at Week 2 (n=201, n=203)Number of remitters at Week 3 (n=202, n=204)Number of remitters at Week 4 (n=202, n=204)Number of remitters at Week 6 (n=202, n=204)Number of remitters at Week 8 (n=202, n=204)
Placebo92432434765
Trazodone Contramid OAD102951616672

[back to top]

HAMD-17 Responders at Each Visit

Number of patients who show a response (defined as at least a 50% reduction from baseline in HAMD-17 score) at each post-baseline visit. (NCT00775203)
Timeframe: Weeks 1, 2, 3, 4, 6, 8

,
InterventionParticipants (Number)
≥50% reduction in HAMD-17 at Week 1 (n=197, n=199)≥50% reduction in HAMD-17 at Week 2 (n=201, n=203)≥50% reduction in HAMD-17 at Week 3 (n=202, n=204)≥50% reduction in HAMD-17 at Week 4 (n=202, n=204)≥50% reduction in HAMD-17 at Week 6 (n=202, n=204)≥50% reduction in HAMD-17 at Week 8 (n=202, n=204)
Placebo194153748184
Trazodone Contramid OAD25638995100109

[back to top]

Overall Quality of Sleep at Each Visit

"Overall Quality of Sleep was measured on a 4-point rating scale ranging from 1 = very poor to 4 = excellent in response to the question: Since the last study visit, how would you rate the overall quality of your sleep?." (NCT00775203)
Timeframe: Weeks 1, 2, 3, 4, 6, 8

,
InterventionPoints on a scale (Mean)
Score at Baseline (n=202, n=204)Score at Week 1 (n=196, n=199)Score at Week 2 (n=200, n=203)Score at Week 3 (n=201, n=204)Score at Week 4 (n=201, n=204)Score at Week 6 (n=201, n=204)Score at Week 8 (n=201, n=204)
Placebo1.60.40.70.70.70.90.8
Trazodone Contramid OAD1.60.70.80.91.01.01.0

[back to top]

Trouble Falling Asleep at Each Visit

"Trouble Falling Asleep was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: Since the last study visit, how often did you experience trouble falling asleep?." (NCT00775203)
Timeframe: Weeks 1, 2, 3, 4, 6, 8

,
InterventionUnits on a scale (Mean)
Score at Baseline (n=202, n=204)Score at Week 1 (n=196, n=199)Score at Week 2 (n=200, n=203)Score at Week 3 (n=201, n=204)Score at Week 4 (n=201, n=204)Score at Week 6 (n=201, n=204)Score at Week 8 (n=201, n=204)
Placebo2.92.62.52.32.32.32.3
Trazodone Contramid OAD3.02.52.32.22.12.12.1

[back to top]

Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit

"Patients were responders if the CGI-I rating was Much Improved or Very Much Improved. The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: Compared to his condition at the start of the study, how much has this patient changed? which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients." (NCT00775203)
Timeframe: Week 8

Interventionparticipants (Number)
Trazodone Contramid OAD96
Placebo89

[back to top]

Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]

(NCT00839072)
Timeframe: 24 hours

Interventionng*h/mL (Mean)
Trazodone Contramid® OAD16885.8
Desyrel®22512.8

[back to top]

Bioequivalence Based on AUC∞

AUC∞ = Area under the concentration-time curve extrapolated to infinity (NCT00839072)
Timeframe: 72 hours post-dose

Interventionng*h/mL (Mean)
Trazodone Contramid® OAD30913.7
Desyrel®37273.4

[back to top]

Bioequivalence Based on AUCT

AUCT = Area under the concentration-time curve from 0 to the time of the last quantifiable concentration (NCT00839072)
Timeframe: 72 hours post-dose

Interventionng*h/mL (Mean)
Trazodone Contramid® OAD29180.6
Desyrel®36002.4

[back to top]

Bioequivalence Based on Cmax

Cmax = Maximum plasma concentration Measured in nanograms per millilitre (ng/mL) (NCT00839072)
Timeframe: 72 hours post-dose

Interventionng/mL (Mean)
Trazodone Contramid® OAD1060.8
Desyrel®1743.3

[back to top]

Time of Maximum Measured Plasma Concentration (Tmax)

(NCT00839072)
Timeframe: 72 hours post-dose

Interventionhours (Median)
Trazodone Contramid® OAD6.00
Desyrel®9.50

[back to top]

Apparent Terminal Elimination Half-Life [T½el]

The elimination half-life (T½el) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours. (NCT00839072)
Timeframe: 72 hours post-dose

InterventionHours (Mean)
Trazodone Contramid® OAD14.37
Desyrel®12.16

[back to top]

Apparent Terminal Elimination Rate Constant (λz)

The elimination rate constant of trazodone (Lamda z). It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour. This constant is used in half-life calculations. (NCT01121900)
Timeframe: 68 hours

Intervention1/hour (Mean)
Trazodone Contramid® OAD0.064
Trazodone IR (Apotex Corp.)0.090

[back to top]

Apparent Terminal Half-life (t½.z)

The elimination half-life (T½z) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours. (NCT01121900)
Timeframe: 68 hours

InterventionHours (Mean)
Trazodone Contramid® OAD11.8
Trazodone IR (Apotex Corp.)8.3

[back to top]

Area Under the Plasma Concentration vs. Time Data Pairs, for the First 24 Hours [AUC(0-24)]

(NCT01121900)
Timeframe: 24 hours

Interventionh*ng/mL (Mean)
Trazodone Contramid® OAD18331.0
Trazodone IR (Apotex Corp.)24602.2

[back to top]

Bioequivalence Based Cmax

Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL). (NCT01121900)
Timeframe: 68 hours

Interventionng/mL (Mean)
Trazodone Contramid® OAD1230.7
Trazodone IR (Apotex Corp.)2947.7

[back to top]

Bioequivalence Based on AUC(0-∞)

"AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).~Measured in nanogram x hours per milliliter (ng*h/mL)." (NCT01121900)
Timeframe: 68 hours

Interventionh*ng/mL (Mean)
Trazodone Contramid® OAD29672.5
Trazodone IR (Apotex Corp.)35258.5

[back to top]

Bioequivalence Based on AUC(0-tlast)

"AUC(0-tlast) = Area under the plasma concentration curve (AUC) vs (versus) time data pairs, where tlast is the time of the last quantifiable concentration.~Measured in nanogram x hours per milliliter (ng*h/mL)." (NCT01121900)
Timeframe: 68 hours

Interventionhr*ng/mL (Mean)
Trazodone Contramid® OAD28138.4
Trazodone IR (Apotex Corp.)34272.4

[back to top]

Time to Maximum Plasma Concentration (Tmax)

(NCT01121900)
Timeframe: 68 hours

InterventionHours (Median)
Trazodone Contramid® OAD9.00
Trazodone IR (Apotex Corp.)8.33

[back to top]

Apparent First Order Terminal Rate Constant [λz]

Apparent First order terminal rate constant [λz] of trazodone in plasma expressed in 1/hours. (NCT01121913)
Timeframe: 72 hours

Intervention1/hours (Mean)
Trazodone Contramid® OAD (Prototype 1)0.07
Trazodone Contramid® OAD (Prototype 2)0.07
Triticco®0.07
Desyrel®0.08

[back to top]

Apparent Terminal Half-life (t½.z)

Apparent terminal half-life (t½.z) of trazodone in hours (NCT01121913)
Timeframe: 72 hours

InterventionHours (Mean)
Trazodone Contramid® OAD (Prototype 1)11.2
Trazodone Contramid® OAD (Prototype 2)10.9
Triticco®10.6
Desyrel®9.77

[back to top]

Bioequivalence Based on AUC(0-∞)

"AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).~Measured in nanogram x hours per milliliter (ng*h/mL)." (NCT01121913)
Timeframe: 72 hours

Interventionng*h/mL (Mean)
Trazodone Contramid® OAD (Prototype 1)35122
Trazodone Contramid® OAD (Prototype 2)33373
Triticco®34165
Desyrel®32485

[back to top]

Bioequivalence Based on AUC(0-t)

"AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration.~Measured in nanogram x hours per milliliter (ng*h/mL)." (NCT01121913)
Timeframe: 72 hours

Interventionng*h/mL (Mean)
Trazodone Contramid® OAD (Prototype 1)33883
Trazodone Contramid® OAD (Prototype 2)32445
Triticco®32928
Desyrel®31841

[back to top]

Bioequivalence Based on Cmax

Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL). (NCT01121913)
Timeframe: 72 hours

Interventionng/mL (Mean)
Trazodone Contramid® OAD (Prototype 1)1260
Trazodone Contramid® OAD (Prototype 2)1475
Triticco®1688
Desyrel®2081

[back to top]

Time to the Maximum Concentration (Tmax)

(NCT01121913)
Timeframe: 72 hours

InterventionHours (Median)
Trazodone Contramid® OAD (Prototype 1)12.0
Trazodone Contramid® OAD (Prototype 2)6.00
Triticco®13.0
Desyrel®8.50

[back to top]

Bioequivalence Based on AUCss

"AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss.~Measured in nanograms x hours per milliliter (ng*h/mL)." (NCT01121926)
Timeframe: 9 days

Interventionng*h/mL (Mean)
Trazodone Contramid® OAD29131.374
Trazodone HCl (Apotex Corp.)33058.024

[back to top]

Bioequivalence Based on Cmax,ss

Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL). (NCT01121926)
Timeframe: 9 days

Interventionng/mL (Mean)
Trazodone Contramid® OAD1812.026
Trazodone HCl (Apotex Corp.)3117.778

[back to top]

Minimum Plasma Concentration (Cmin,ss)

Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL) (NCT01121926)
Timeframe: 9 days

Interventionng/mL (Mean)
Trazodone Contramid® OAD673.889
Trazodone HCl (Apotex Corp.)842.763

[back to top]

Percentage Peak-Trough Fluctuation (%PTF)

"Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as [100*(Cmax-Cmin)/Cav].~Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration" (NCT01121926)
Timeframe: 9 days

InterventionPercentage Peak-Trough Fluctuation (Mean)
Trazodone Contramid® OAD97.090
Trazodone HCl (Apotex Corp.)174.768

[back to top]

Percentage Swing

"Percentage swing is a pharmacokinetic parameter calculated as follows:~((Cmax,ss - Cmin,ss)/Cmin,ss)*100.~Where:~Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state.~It was calculated over 24 hours on day 9." (NCT01121926)
Timeframe: 9 days

InterventionPercentage swing (Mean)
Trazodone Contramid® OAD210.769
Trazodone HCl (Apotex Corp.)302.805

[back to top]

Plasma Concentration at 24 Hours Post-evening Dose (C24h)

Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL) (NCT01121926)
Timeframe: 9 days

Interventionng/mL (Mean)
Trazodone Contramid® OAD747.270
Trazodone HCl (Apotex Corp.)919.111

[back to top]

Time to Peak Exposure (Tmax)

Time to peak exposure (Tmax) at steady state. (NCT01121926)
Timeframe: 9 days

Interventionhours (Median)
Trazodone Contramid® OAD8.00
Trazodone HCl (Apotex Corp.)8.33

[back to top]

Change in Objective Actigraphy Sleep Duration From Baseline to Follow up (9 Months)

Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and follow up (9 months) (NCT01348542)
Timeframe: Baseline to follow up (9 months)

Interventionminutes (Mean)
Trazodone50.35
Cognitive Behavioral Therapy-7.56

[back to top]

Change in Objective Actigraphy Sleep Duration From Baseline to Post Treatment (3 Months)

Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and Post Treatment (3 months) (NCT01348542)
Timeframe: Baseline to Post Treatment (3 months)

Interventionminutes (Mean)
Trazodone51.01
Cognitive Behavioral Therapy-11.73

[back to top]

Change in Objective Polysomnography Sleep Duration From Baseline to Follow up (9 Months)

Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and follow up (9 months) (NCT01348542)
Timeframe: Baseline to follow up (9 months)

Interventionminutes (Mean)
Trazodone51.78
Cognitive Behavioral Therapy32.36

[back to top]

Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months)

Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and post treatment (3 months) (NCT01348542)
Timeframe: Baseline to Post Treatment (3 months)

Interventionminutes (Mean)
Trazodone28.95
Cognitive Behavioral Therapy38.91

[back to top]

Change From Baseline in Subjective Severity of Sleep Disturbance at 3 Months

The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to post treatment (3 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms. (NCT01348542)
Timeframe: Baseline to Post Treatment (3 months)

Interventionscore on a scale (Mean)
Trazodone-12.29
Cognitive Behavioral Therapy-10.75

[back to top]

Change From Baseline in Subjective Severity of Sleep Disturbance at 9 Months

The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to Follow Up (9 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms. (NCT01348542)
Timeframe: Baseline to follow up (9 months)

Interventionscore on a scale (Mean)
Trazodone-13.29
Cognitive Behavioral Therapy-10.38

[back to top]

Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index

The Insomnia Severity Index (ISI) is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Remission is determined to be a score less-than 8. (NCT01651442)
Timeframe: 6 weeks, 12 weeks, 3 months, 6 months, 9 months & 12 months

Interventionpercent remitted (Number)
Non-drug Sleep Therapy 140.00
Sleep Medication 134.94
Sleep Medication 1 Plus Non-drug Sleep Therapy 137.04
Sleep Medication 1 Plus Sleep Medication 248.15
Non-drug Sleep Therapy 1 Plus Non-drug Sleep Therapy 144.44
Non-drug Sleep Therapy 1 Plus Sleep Medication 155.56

[back to top]

Change in Insomnia Severity Index (ISI) Scores

THE RANGE OF SCORES IS FROM 0-28, WITH 28 REPRESENTING SEVERE INSOMNIA SYMPTOMS. Measurements made and reported at baseline, week 2, week 4. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. . This is a comparison between groups (trazodone versus quetiapine)of the change on TOTAL ISI scores over time using repeated measures analysis. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8). (NCT01662297)
Timeframe: from baseline (week 0) to the end of week 4 and at week 8

Interventionunits on a scale (Mean)
change at week 4change at week 8
Trazodone-14-16

[back to top]

Change in Alcohol Urge Questionnaire (AUQ)Scores Over Time

The lowest possible score for the AUQ is 8 (representing less urge to drink) and the highest score would be a 56 (more urge to drink). Measurements made at baseline, week 2, week 4, week 8. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. This is a comparison between groups (trazodone versus quetiapine)of the change on AUQ scores over time. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8). (NCT01662297)
Timeframe: from week 0 (baseline) to end of week 8

Interventionunits on a scale (Mean)
change after week 4change after week 8
Trazodone-1-12

[back to top]

Change in Average Pittsburgh Sleep Quality Inventory (PSQI)Score

Data analyzed for change from score at baseline, to week 4, to week 8. The range of scores is 0-21 on this scale, with higher scores indicating worse sleep quality. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. This is a comparison between groups (trazodone versus quetiapine)of the change on TOTAL PSQI scores over time using repeated measures analysis. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. The first four weeks of treatment is the active acute experiment phase, and this will be the main comparison time period for the endpoint, but the investigators will also analyze change in PSQI until the follow-up point at the end of week 8. (NCT01662297)
Timeframe: From baseline (week 0) to end of 4 week and end of week 8

Interventionunits on a scale (Mean)
change at week 4change at week 8
Trazodone-11-11

[back to top]

Change in Brief Symptom Inventory (BSI) Over Time

The Brief Symptom Inventory scale measures a broad range of psychiatric symptoms (psychological distress) and is meant to provide an overall measure of mental health symptomatology. The BSI has 53 items that use a 5-item Likert scale response. In general, higher scores correspond to greater symptomatology and distress. Usually, the range of scores goes from 0 - 4, since it is averaged over the number of responses, however, we report the raw total score which is the sum of all responses, thus the range is 0-212. Measurements made at baseline, week 2, week 4, week 8. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. This is a comparison between groups of the change on BSI scores over time using repeated measures analysis. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. (NCT01662297)
Timeframe: from week 0 (baseline) to end of week 8

Interventionunits on a scale (Mean)
change at week 4change at week 8
Trazodone-48-48

[back to top]

Change in Epworth Sleepiness Scale (ESS) Over Time

Measurements made at baseline, week 2, week 4, week 8. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. The change from week 4 to week 8 (post-intervention) will also be measured and analyzed, reported. This is a comparison between groups (trazodone versus quetiapine)of the change on ESS scores over time using repeated measures analysis. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8).The minimum score on ESS is 0-24 units, with higher score representing greater sleepiness. (NCT01662297)
Timeframe: From baseline (week 0) to end of week 8

Interventionunits on a scale (Mean)
change at week 4change at week 8
Trazodone-3-4

[back to top]

Change in RAND Short Form 36 Item Health Survey (RAND-SF36) General Health Subscale Over Time

Scores range from 0-100 representing percentage, with a higher score representing better functioning. Measurements made at baseline, week 2, week 4, week 8. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. The change from week 4 to week 8 (post-intervention) will also be measured and analyzed, reported. This is a comparison between groups (trazodone versus quetiapine)of the change on RAND-SF36 scores over time. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8). (NCT01662297)
Timeframe: from week 0 (baseline) to end of week 8

Interventionpercentage of total points possible (Mean)
change at week 4change at week 8
Trazodone150

[back to top]

Medical Outcomes Study Sleep Scale- Sleep Index (Short)

THE RANGE OF SCORES IS FROM 0-100, WITH 100 REPRESENTING SEVERE INSOMNIA SYMPTOMS. Measurements made and reported at baseline, week 2, week 4. Data will be presented and analyzed for those time points with the main outcome measured as the change from baseline to week 4. . This is a comparison between groups (trazodone versus quetiapine)of the change on TOTAL MOS-SS scores over time using repeated measures analysis. This is a non-superiority analysis, so the hypothesis is that there is no significant difference between treatments. The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8). (NCT01662297)
Timeframe: from baseline (week 0) to the end of week 8 sample

Interventionunits on a scale (Mean)
change at 4 weekschange at 8 weeks
Trazodone-13.33-26.66

[back to top]

Percentage of Heavy Drinking Days

This is a comparison between groups of the mean percent heavy drinking days during the first 4 weeks, and then through to the follow up point (end of week 8). The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8). (NCT01662297)
Timeframe: from week 0 (baseline) to end of week 8

Interventionpercentage of heavy drinking days (Mean)
percentage at week 4percentage at week 8
Trazodone00

[back to top]

Percentage of Negative Urine Drug Screens

This is a comparison between groups of the mean percent of negative urine drug screens. The investigators will first report the comparison during the active treatment phase (baseline to end of week 4) as the main comparison, but will also examine and report changes on the outcome at the follow up point (end of week 8). THIS IS A CUMULATIVE PERCENTAGE. MAXIMUM SCORE IS 100%, MINIMUM 0%. (NCT01662297)
Timeframe: from week 0 (baseline) to end of week 8

Interventionpercentage of tests (Mean)
cumulative percentage at week 4cumulative percentage at week 8
Trazodone00

[back to top]

Apnea-Hypopnea Index

The Apnea-Hypopnea Index (AHI) is an index of sleep apnea severity that encompasses the frequency of apneas (cessations in breathing) and hypopneas (reductions in airflow). (NCT01817907)
Timeframe: Participants will be assessed on 2 nights over an average period of 2 weeks.

Interventionevents/hour (Mean)
Placebo38.7
Trazodone28.5

[back to top]

Arousal Threshold (cmH2O)

Subjects will have an epiglottic pressure catheter placed during their sleep studies. We will use the swing in the epiglottic pressure trace just prior to arousal to calculate the respiratory drive stimulus that is associated with an a respiratory induced arousal. (NCT01817907)
Timeframe: Participants will be assessed on 2 nights over an average period of 2 weeks.

InterventioncmH2O (Mean)
Placebo-19.3
Trazodone-20.3

[back to top]

Self Paced Walking Test (SPWT)

Our primary aim also included a performance-based outcome measure, which was the distance walked during the SPWT. The analysis was a comparison of between-group changes in SPWT between baseline and 8 weeks. The Self-Paced Walking Test (SPWT) is a validated objective measure of a patient's walking capacity, which is performed on a level walking surface. The patient is instructed to walk at their own pace and to stop when the symptoms are troublesome enough that s/he needs to sit down to rest. The total time and total distance walked are measured by the research assistant. Our unit of measure was the total distance walked, expressed in meters. (NCT01943435)
Timeframe: Primary end-point was 8 weeks ( 2 weeks after 6 week intervention is completed).

Interventionmeters (Mean)
Medical Care130.5
Group Exercise219.2
Manual Therapy and Exercise267.8

[back to top]

Sense Wear Armband

Our secondary aim was to measure the change in physical activity between baseline and 8 weeks using the Sense Wear armband (SWA). The outcome measure was the average number of minutes spent daily performing physical activities >1.5 metabolic equivalents (METs).The SWA is a small device that collects information from multiple sensors: a triaxial accelerometer, heat flux, skin temperature, and galvanic signal. The information is integrated and processed by software using proprietary algorithms utilizing subjects' demographic characteristics (gender, age, height, and weight) to provide minute-by-minute estimates of physical activity. The SWA has shown good reliability and validity. The research participants in our study will wear the SWA for a week before and after they complete the treatment interventions. (NCT01943435)
Timeframe: Primary End-Point was 8 weeks ( 2 weeks after completion of 6-week intervention).

Interventionminutes per day (Mean)
Medical Care-23.1
Group Exercise4.3
Manual Therapy and Exercise-6.0

[back to top]

Swiss Spinal Stenosis (SSS) Questionnaire Score

Our primary aim included a primary outcome measure of self-reported pain/function, which was the change in SSS total score between baseline and 8 weeks. The Swiss Spinal Stenosis Questionnaire (SSS) is a validated 12-item condition-specific instrument for patients with lumbar spinal stenosis. It provides a patient self-report measure of pain and physical function. Higher scores represent worse symptoms and less physical function. The 12-item SSS total score range is 12-55. For our analysis, we compared the change in the 12-item Total score from baseline to 8 weeks. (NCT01943435)
Timeframe: Primary End-Point was 8 weeks ( 2 weeks after completion of 6-week intervention).

Interventionunits on a scale (Mean)
Medical Care-2.0
Group Exercise-1.7
Manual Therapy and Exercise-4.1

[back to top]

CO2 Reserve (Delta-PETCO2-AT)

Randomized placebo-controlled cross-over study. Each subject was studied on three separate occasions: (1) Buspirone vs. Trazodone vs. placebo for 2 weeks; After the two-week treatment a noninvasive nasal mechanical ventilation study was repeated to determine the hypocapnic apneic threshold. (2) Cross over medication for two weeks was followed by a second noninvasive nasal mechanical ventilation study to determine the CO2 reserve (Delta-PETCO2-AT) and hypocapnic apneic threshold followed by two weeks washout. (3) Cross over medication for two weeks was followed by another sleep study to determine the hypocapnic apneic threshold. (NCT02458469)
Timeframe: Two weeks

InterventionmmHg (Mean)
Buspirone-3.6
Trazodone-2.5
Placebo-1.8

[back to top]

Apnea-Hypopnea Index (AHI)

Randomized placebo-controlled cross-over study. Each subject was studied on three separate occasions: (1) Buspirone vs. Trazodone vs. placebo for 2 weeks; After the two-week treatment a polysomnogram (PSG) study was repeated to determine the AHI. (2) Cross over medication for two weeks was followed by a second PSG to determine the AHI followed by two weeks washout. (3) Cross over medication for two weeks was followed by another sleep study to determine the AHI. (NCT02458469)
Timeframe: Two weeks

InterventionEvents/Hour (Mean)
Buspirone48.7
Trazodone40.0
Placebo45.2

[back to top]

Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury

The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-2.04-1.69-1.81
Usual Care-1.90-1.63-1.45

[back to top]

Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury

The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-0.79-1.17-1.84
Usual Care-0.50-0.90-2.16

[back to top]

Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury

The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-1.65-4.02-5.51
Usual Care0.08-1.44-4.25

[back to top]

Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury

The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-16.78-14.17-13.23
Usual Care-15.90-13.83-11.68

[back to top]

Cognitive Impairment Scale

The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention13.513.313.213.8
Usual Care13.413.213.414.2

[back to top]

Number of Participants Endorsing a Single Item That Assesses Marijuana Use

Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention125606051
Usual Care177728279

[back to top]

Number of Participants Endorsing a Single Item That Assesses Opioid Use

Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention18446
Usual Care4415206

[back to top]

Number of Participants Endorsing a Single Item That Assesses Stimulant Use

Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention58978
Usual Care77172216

[back to top]

Number of Participants With Suicidal Ideation

Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention67696351
Usual Care909910692

[back to top]

SF-36 Quality of Life

The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention44.338.338.439.2
Usual Care45.139.139.541.4

[back to top]

TSOS Patient Satisfaction: Mental Health Care

Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3 Month, 6 Month, 12 Month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.13.63.63.7
Usual Care4.03.53.43.5

[back to top]

Brief Pain Inventory

A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention6.84.34.13.9
Usual Care6.74.74.53.8

[back to top]

TSOS Patient Satisfaction: Overall Health Care

Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.43.94.03.9
Usual Care4.43.83.83.8

[back to top]